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1.1 Abstract (English) 
Introduction: Several lines of evidence indicate that aggregation and accumulation of 
amyloid-β(1-42) (Aβ42) causes cellular dysfunction and toxicity. Besides extracellular 
Aβ42 plaque formation and the intraneuronal deposition of hyperphosphorylated tau 
protein in Alzheimer’s disease (AD) patient brains, intracellular Aβ42 aggregation plays 
an important role in AD pathogenesis and even precedes extracellular Aβ42 plaque 
formation. The fact that neuronal cells internalize secreted Aβ42 whereby intracellular 
Aβ42 aggregation is induced by a prion-like seeding process, has further highlighted the 
importance of intraneuronal Aβ42 aggregation in disease progression. A potential causal 
therapy of AD involves slowing disease progression by targeting seeding-competent 
intracellular Aβ42 aggregates and enhancing their degradation in neuronal cells. 
Method: Therefore, a cell-based screening assay was established that allows the ident-
ification of small molecules effectively promoting the degradation of endocytotically 
internalized Aβ42 aggregates. This cell-based assay was intensively characterized and 
used in a proof-of-principle approach to screen a focused library of polyphenolic 
compounds preselected based on their anti-amyloidogenic properties in vitro. Further, 
atomic force, electron and confocal microscopy, biochemical analysis and enzyme activity 
assays were used and structure-activity relationship studies were performed to elucidate 
the mechanisms underlying the promotion of cellular aggregate degradation by direct 
amyloid-targeting compounds. 
Results: The polyphenol epigallocatechin gallate (EGCG) most potently promoted the 
clearance of intracellular Aβ42 aggregates in the neuroblastoma cell model. As a 
consequence of EGCG treatment, intracellular Aβ42 aggregate load is reduced, Aβ42 
seeding-activity of cellular extracts is mitigated and Aβ42-induced mitochondrial 
metabolic impairment is rescued in neuroblastoma cells as well in primary neurons. 
Mechanistic studies revealed that EGCG directly targets intracellular Aβ42 aggregates 
and that the EGCG-mediated increase in Aβ42 degradation is primarily dependent on 
lysosomal enzyme activity. Furthermore, EGCG-induced structural remodeling of fibrillar 
Aβ42 aggregates into amorphous subspecies showed to enhance lysosomal enzymatic 
cleavage by the cysteine-protease cathepsin B (CatB), presenting a potential mechanism 






Take home points: Thus, this study shows that the direct targeting of intracellular Aβ42 
aggregates with amyloid-remodeling compounds can be a promising approach to pro-
mote the degradation of proteotoxic peptide species. This can be an effective strategy to 
support the endogenous autophago-lysosomal degradation of intracellularly accumu-
lating proteins in neurodegenerative proteinopathies such as amyotrophic lateral scle-






1.2 Abstract (German) 
Einleitung: Zahlreiche Studien haben gezeigt, dass die Aggregation und Akkumulation 
von Amyloid-β(1-42) (Aβ42) eine zelluläre Dysfunktion und Zelltoxizität zur Folge haben. 
Neben der Entstehung von extrazellulären Aβ42 Plaques und der intrazellulären 
Ablagerung von hyperphosphorylierten Tau Proteinen im neuronalen Gewebe von 
Alzheimer Patienten, spielt die intrazelluläre Ablagerung von Aβ42 Aggregaten eine 
zentrale Rolle in der Pathogenese der Alzheimer-Demenz (AD) und geht der 
extrazellulären Plaque-Bildung sogar voraus. Die Erkenntnis, dass neuronale Zellen 
sekretiertes Aβ42 aufnehmen und dadurch eine intrazelluläre Fehlfaltung in einem 
Prionen-ähnlichen Seeding-Prozess induziert werden kann, lässt der intraneuronalen 
Aβ42 Ablagerung in der molekularen Pathogenese der Krankheitsprogression eine 
besondere Wichtigkeit zukommen. 
Methodik: Aufgrund dessen haben wir ein zellbasiertes Testverfahren entwickelt, mit 
dem niedermolekulare Substanzen identifiziert werden können, welche den Abbau von 
endozytotisch internalisierten, seeding-kompetenten Aβ42 Aggregaten fördern. Mittels 
diesem zellbasierten Screeningverfahren haben wir eine fokussierte Bibliothek aus 
Polyphenol-Verbindungen getestet, die aufgrund ihrer bekannten, anti-amyloidogenen 
Wirkung vorselektiert wurden. Darüber hinaus wurden Rasterkraft-, Elektronen- und 
Konfokalmikroskopie sowie biochemische Proteinanalyse- und Enzymaktivitätsverfahren 
verwendet, um den zugrundeliegenden Mechanismus der Förderung des Abbaus von 
intrazellulären Proteinaggregatspezies durch anti-amyloidogene, niedermolekulare 
Substanzen aufzuklären. 
Ergebnisse: Das Polyphenol Epigallocatechingallat (EGCG) zeigte die potenteste Wir-
kung auf die Reduktion von intrazellulären Aβ42 Aggregaten in unserem Modellsystem. 
Durch die EGCG-Behandlung wird die Menge an intrazellulären Aβ42 Aggregaten stark 
reduziert, die Seeding-Kapazität zellulärer Extrakte abgeschwächt und der durch Aβ42 
induzierten verminderten mitochondrialen Stoffwechselaktivität sowohl in Neuroblas-
toma-Zellen als auch in primären Neuronen entgegengewirkt. Mechanistische Untersu-
chungen offenbarten zudem, dass EGCG direkt an intrazellulären Aβ42 Aggregaten 
ansetzt, dass die Abbau-fördernde Wirkung abhängig von der lysosomalen Enzym-
aktivität ist und, dass die durch EGCG bewirkte, strukturelle Umlagerung von fibrillären 






Cathepsin B erleichtert.  
Fazit: Diese experimentellen Arbeiten zeigen somit, dass Amyloidstruktur-verändernde, 
niedermolekulare Substanzen, die direkt an intrazelluläre Aβ42 Aggregate binden, einen 
vielversprechenden Ansatz zur Reduktion der intrazellulären Aβ42 Last darstellen. Dieser 
Ansatz könnte genutzt werden, um bei proteinopathischen neurodegenerativen 
Erkrankungen wie der amyotrophen Lateralsklerose, Chorea Huntington, Parkinson und 
der Alzheimer Erkrankung die zelleigene Verstoffwechslung von fehlgefalteten, intra-







2.1 Alzheimer’s disease: impact & clinical presentation 
Alzheimer’s disease (AD) represents the most common type of dementia (Wang et al., 
2017). It is an incurable neurodegenerative disease, which is one of the greatest 
challenges for our health system (Winblad et al., 2016). The typical presentation of an 
Alzheimer’s patient is characterized by cognitive decline such as memory impairment, an 
executive dysfunction and difficulties in daily life activities. These characteristic symptoms 
arise usually between the age of 65 and 70, increase in a slow and periodic manner where 
body functions are gradually lost and ultimately leads to death after seven to ten years 
(Scheltens et al., 2016).  
2.2 Epidemiology 
 
Figure 1. Deaths per million persons in 2012 due to dementias including AD (WHO 
2012 & Canuckguy et al.) ___ 
Approximately 40 million people worldwide are affected by dementia. A number, which is 
expected to double every 20 years until 2050 (Prince et al., 2016). As AD is a disease of 
the elderly, developing countries – due to their much older population – are projected to 
have a much higher increase over the coming years compared to Western Europe and 
the USA. Around 30 to 40 percent of dementia cases are from the Alzheimer subtype. 
Other common forms of dementia include vascular dementia, dementia with Lewy bodies 
(LBD) and frontotemporal dementia (FTD). The incidence of AD ranges from 4 to 8 per 
thousand-person years and doubles with the strongest known risk factor, age, every 5 






the observed population. (Mercy et al., 2008). 
2.3 Molecular pathophysiology in Alzheimer’s disease 
The cause for Alzheimer’s disease is still unknown. However, all forms of AD share 
common pathological hallmarks in postmortem tissue: intracellular neurofibrillary tangles 
(NFTs) of phosphorylated tau protein and the extracellular deposition of Aβ peptides 
(Masters et al., 2015). These peptides represent fragments of the thereafter-named 
amyloid precursor protein (APP) and are produced by endoproteolytic cleavage of the 
full-length transmembrane protein (Gandy and DeKosky, 2013).  
The strongest evidence pointing towards Aβ aggregate formation as a causal process in 
AD pathogenesis comes from inherited, familial cases. Here, dominant mutations in the 
catalytic subunits of the APP cleaving enzyme complex – presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2) – lead to an increased production of the longer amyloid-β(1-42) 
(Aβ42) fragment in comparison to amyloid-β(1-40) (Aβ40). The enzymatic variations in 
PSEN1 and PSEN2 are genetically sufficient to cause AD (Gandy and DeKosky, 2013). 
This, so-called, amyloidogenic pathway can also be increased due to mutations in the 
APP protein, affecting its proteolytic cleavage in favor of amyloidogenic Aβ42 – compared 
to the less aggregation-prone Aβ40 peptide isoform. In genetic cases, APP mutations 
lead to an increase of APP cleavage by proteases, which mostly generate Aβ42 peptide 
fragments from APP (O’Brien and Wong, 2011). Additionally, duplication of the APP gene, 
either of the gene locus itself, or the chromosome as in trisomy 21, leads to an increased 
production of Aβ42 peptides and ultimately to the development of an AD phenotype 
(McNaughton et al., 2012). 
Mutations in APP and members of the APP cleaving complexes account for 
approximately 60 to 70 percent of early onset AD, but for less than 1 percent of all AD 
cases, and therefore only explain a small proportion of overall AD clinical cases. 
Additional rare genetic variants were recently identified in two genes, namely TREM2 and 
SORL1 (Guerreiro et al., 2013; N. et al., 2015), which are involved in autophagy and 
lysosomal protein degradation (Buggia-prévot and Thinakaran, 2014; Ulland et al., 2017) 
– cellular mechanisms essential for the processing of misfolded and aggregated peptides 
and proteins in almost all cell types, including neurons (Klionsky, 2007). This emphasizes 
the role of misfolding proteins and their clearance mechanisms in AD pathogenesis. 






clearance mechanisms such as deficiencies in autophagy or lysosomal activity, ultimately 
harm affected neuronal cells and might therefore be accountable for AD (Nikoletopoulou 
et al., 2015; Orr and Oddo, 2013).  
In line with this hypothesis, a recent genetic case-control study that analyzed whole-
exome sequencing data to find AD-related variants in sporadic cases, including late-onset 
AD, was able to identify four genes – PSD2, TCIRG1, RIN3 and RUFY1 – in which mainly 
rare missense variants are strongly associated with late onset and early onset AD (Kunkle 
et al., 2017). Interestingly, all four genes are likely involved in endolysosomal transport 
(Bohdanowicz and Grinstein, 2013; Cataldo et al., 1997; Kajiho et al., 2003; Sun-Wada 
et al., 2009), This further supports the amyloid-hypothesis and highlights the importance 
of cellular Aβ aggregate clearance mechanisms in AD pathogenesis.  
Besides these rather rare genetic risk factors, variants in the apolipoprotein E (ApoE) 
have been established as – by far - the most important susceptibility gene for late-onset 
AD (LOAD) (Bettens et al., 2013). The human APOE gene is located on chromosome 19 
and is encoding three different isoforms: ApoE ε2 (ApoE2), ApoE ε3 (ApoE3) and ApoE 
ε4 (ApoE4). Differences between the isoforms are limited to two amino acid changes, but 
have a rather strong effect on the protein’s structure and function, and a dramatic impact 
on the risk to develop AD (Zhong and Weisgraber, 2009). Genetic variants in the APOE 
gene mainly result in the expression of a certain predominant isoform. The ApoE4 isoform 
hereby represents the main genetic risk factor: one copy of the genetic variant leading to 
ApoEε4 expression results in a five year earlier disease onset, whereas two copies of the 
risk allele shift onset up to 10 years earlier (Noguchi et al., 1993; Pastor et al., 2003). 
Harboring the most common isoform ApoE3 results in an average risk to develop AD, 
whereas being genetically equipped with an ApoE2 isoform acts in a protective way. 
Interestingly, the increased risk of ApoE4 carriers to develop AD is directly associated 
with an increased deposition of misfolded Aβ (ApoE4 > ApoE3 > ApoE2). This has been 
clearly shown in AD animal models as well as in human studies (Bales et al., 2009; 
Castellano et al., 2011; Koffie et al., 2012; Youmans et al., 2012). Furthermore, it has 
been found that ApoE is strongly involved in Aβ clearance and in maintaining Aβ in a 
soluble rather than in an insoluble, aggregated state (Bu et al., 2012; Tai et al., 2013). 
ApoE in fact, directly interacts with Aβ and the subsequent binding of ApoE to membrane 
proteins, such as the low-density lipoprotein receptor (LDLR), the low-density receptor-






uptake (Bu et al., 2012; Carlo et al., 2013). Most notably, when the interaction between 
Aβ and ApoE is blocked, intraneuronal accumulation of Aβ is reduced (Kuszczyk et al., 
2013). 
Thus, the genetic landscape of AD-associated mutations and risk variants results in, on 
the one hand, an increased production of the aggregation-prone Aβ42 peptide isoforms 
from its precursor protein and, on the other hand, affects cellular uptake and clearance 
mechanisms of misfolded proteins on multiple levels. Ultimately, this might lead to an 
excessive disturbance of cellular protein homeostasis, where intracellular protein 
aggregates sequester essential factors of cellular functions (Yang and Hu, 2016). 
Furthermore, constant recycling of misfolded, aggregated proteins and peptides is of high 
importance, in order to maintain a sufficient, cellular energy metabolism. Thus, 
malfunctions in endosomal-lysosomal uptake and autophagic flux, might finally result in 
metabolic dysregulation, cellular nutritional deficiencies and neuronal cell death (Kaur 
and Debnath, 2015; Singh and Cuervo, 2011).  
2.4 Intracellular Aβ42 deposition and cellular degradation 
As introduced above, even though the pathological hallmark of AD was initially described 
as extracellular Aβ plaque formation, Aβ peptides do not only accumulate extracellularly, 
but also form insoluble intracellular aggregates in neuronal cells (LaFerla et al., 2007; 
Ripoli et al., 2014; Takahashi et al., 2017). In transgenic mouse models of AD, the 
formation of intracellular Aβ aggregates is generally observed prior to the appearance of 
extracellular amyloid plaques, indicating that intracellular aggregate formation is an early 
event in pathogenesis potentially preceding extracellular Aβ plaque deposition 
(Takahashi et al., 2013). Additionally, the intracellular accumulation of Aβ peptides could 
also be found prior to extracellular plaque formation in AD patients with Down Syndrome 
(Gyure et al., 2001). 
Within the cytoplasm of neurons in AD patients, individual endosomes in fact show 
dramatically enlarged volumes when compared to their sizes in unaffected individuals 
indicating intracellular Aβ42 aggregate deposition in the endolysosomal compartment 
(Cataldo et al., 2004). APP itself can be internalized into early-endosomes and is 
discussed to be processed within the endocytotic pathway, which thereby represents a 
location of intracellular Aβ42 generation (Cabrejo et al., 2006; Martin et al., 1995; Rovelet-






the endocytotic and endolysosomal pathway, degradation of misfolded, accumulated 
proteins such as Aβ42 is mediated. In fact, some of the earliest pathologic changes in AD 
are characterized by accumulation of Aβ peptides within this endolysosomal system, 
suggesting a malfunction of this essential pathway (Peric and Annaert, 2015). Even in 
blood exosomes from yet cognitively normal individuals, which later developed AD, 
increased levels of autolysosomal proteins are detectable, indicating a very early 
intracellular Aβ accumulation and lysosomal dysfunction in AD pathogenesis (Goetzl et 
al., 2015).  
Additionally, recent studies have shown that neurons and glia can internalize extracellular 
Aβ aggregate species through receptor-mediated endocytosis to remove these structures 
from the extracellular space (Yeh et al., 2016). However, Aβ aggregates entering 
mammalian cells were shown to be able to convert soluble intracellular Aβ polypeptides 
into an aggregated state through a prion-like seeding mechanism (Fritschi et al., 2014; 
Sowade and Jahn, 2017). Thus, neuronal and glial uptake of Aβ peptides or Aβ 
aggregates and their subsequent degradation in the endolysosomal system are very likely 
important processes in controlling Aβ levels, and malfunctions in this processing 
pathways might therefore sustain the pathological cascade in AD. In fact, spreading of 
Aβ peptides via cell-to-cell transfer was shown to be dependent on insufficient cellular 
clearance and thereby potentially drives disease progression (Domert et al., 2014). Thus, 
reduction of the Aβ42 load within the central nervous system and in particular, enhanced 
degradation of intracellular Aβ42 aggregates could be a promising approach to slow 
neurodegeneration and progression in AD.  
2.5 Molecular therapeutic strategies in Alzheimer’s disease 
As deposition of Aβ peptides is a major pathological hallmark of AD and insufficient 
clearance mechanisms might account for disease, numerous efforts to pharmacologically 
lower the Aβ load in brains have been undertaken (Cummings et al., 2014; Doody et al., 
2014; Salloway et al., 2014). One of the first strategies followed was to find inhibitors of 
proteases mainly responsible for cleavage of the APP protein in favor of the 
amyloidogenic Aβ42 peptide. As amyloidogenic peptides are generated by cleavage of 
the APP fragment by the y-secretase complex (Zhang et al., 2011), one logical approach 
was to find inhibitors of this protease and thereby decrease cleavage and ultimately 
reduce the production of aggregation-prone Aβ42 peptides (Wolfe, 2012). Different y-






preclinical studies clearly showed a reduction in brain Aβ42 deposition and a reduction of 
cognitive decline in rodent AD models (Stanton et al., 2010). Furthermore, high 
concentrations of y-secretase inhibitors in phase II trials were able to effectively block 
Aβ42 production in humans, giving hope for this therapeutic approach (Wolfe, 2012). 
However, the unforeseen side effect of γ-secretase inhibitors, inhibition of notch signaling 
– a highly conserved pathway involved in neurogenesis (Artavanis-Tsakonas et al., 1999) 
severely limited dosage in coming phase III trials due to safety concerns (Coric et al., 
2012; Doody et al., 2013). Currently, γ-secretase inhibitors are therefore under 
optimization in order to increase specificity and to reduce inhibition of notch signaling 
(Strömberg et al., 2015). 
As initial cleavage of APP by β-site amyloid precursor protein cleaving enzyme 1 (BACE1) 
is a prerequisite for subsequent generation of amyloidogenic Aβ peptides from the APP 
fragment C99 by y-secretase (Zhang et al., 2011), additionally, BACE1 inhibitors were 
developed as Aβ42 lowering and potential AD disease-modifying drugs. However, 
BACE1 inhibitors, which went into clinical trials, were not able to improve clinical 
outcomes for AD patients. A leading theory for failure, besides insufficient potency or poor 
pharmacokinetics, is that therapeutics aiming at lowering Aβ42 production would need to 
unfold their effects very early in the course of disease to be able to delay 
neurodegeneration (Mullard, 2017). Therefore, BACE1 inhibitors are now being evaluated 
in patient cohorts with prodromal AD (Cummings et al., 2017). 
Another therapeutic approach is the development of Aβ-specific antibodies to reduce Aβ 
pathology in AD patient brains and thereby slow cognitive decline. Currently, there are 
still ongoing clinical trials evaluating Aβ-specific antibodies (Cummings et al., 2017). 
However, so far all Aβ-targeting antibodies, even though able to reduce cerebral amyloid 
plaque load, have failed to exhibit significant positive effects on neurodegeneration and 
clinical outcome (Mullard, 2017). At first, most Aβ targeting antibodies were raised against 
the aggregation-prone Aβ42 peptide species (Prins and Scheltens, 2013). It is not clear 
however, whether these antibodies would still recognize the APP protein and might 
therefore not be able to trigger sufficient immune response and induce adequate 
phagocytosis of misfolded, accumulated Aβ42 aggregate species. Regarding this, 
specific antibodies were raised against neo-epitopes on the surface of aggregated Aβ 
species (Prins and Scheltens, 2013; van Dyck, 2017). One of the most promising 






which was isolated from a memory B-cell of a healthy-aged, elderly individual (Sevigny et 
al., 2016). As Aβ aggregate formation and deposition is not restricted to AD patients, but 
also affects healthy-aged individuals, there might be protective antibodies within the 
central nervous system’s (CNS) antibody repertoire of elderly individuals (Geylis et al., 
2005). Potentially, Aβ aggregate or Aβ seed-targeting antibodies are able to slow disease 
progression by preventing cell-to-cell transfer and spreading of misfolded Aβ throughout 
the CNS. 
An additional strategy lies in the identification of direct Aβ aggregation modulating small 
molecules. It was previously shown that Aβ-binding molecules are capable of interfering 
with Aβ aggregation, thereby slowing down the formation of compact, β-sheet-rich 
structures or furthermore, redirecting the aggregation cascade towards a different 
substructure, which exhibits less toxic effects to neuronal cells (Bieschke et al., 2011; Nie 
et al., 2011). In fact, numerous small molecules, are currently under clinical evaluation 
(Parsons and Rammes, 2017). Besides small molecules, which show beneficial 
neuroprotective, anti-inflammatory, metabolic effects or counteract neurotransmitter 
imbalance in AD, direct, anti-amyloid compounds represent 13% of the current AD drug 
pipeline (Cummings et al., 2017). One major aim of this approach is to inhibit the 
formation of toxic, oligomeric Aβ peptide species, which – in the role of so-called “amyloid-
β derived diffusible ligands” (ADDLs) (Liu et al., n.d.) (Wen et al., 2018) – specifically bind 
to postsynaptic receptors and thereby act as neurotoxins (Shi et al., 2016).  
As stated above, the endolysosomal system and autophagic flux are the major pathways 
identified to be responsible for Aβ clearance. Therefore, enhancing autophagic clearance 
represents an additional potential strategy to increase Aβ aggregate degradation. In fact, 
increasing degradation by autophagy-stimulating compounds does result in increased Aβ 
clearance (Kovács et al., 2017; Tian et al., 2011). Most recently, it was shown that 
boosting endogenous clearance mechanisms by increasing expression of sequestosome 
1 – also known as ubiquitin-binding protein p62, an autophagosome cargo protein, which 
marks other proteins for selective autophagy – does efficiently lower Aβ load and rescues 
cognitive deficits in an AD mouse model (Caccamo et al., 2017). Ultimately, small 
molecules directly targeting accumulating Aβ aggregates in cells, could potentially 
combine both effects: leading to the formation of less proteotoxic amyloid species and 
enhancing degradation through a compound-mediated conformational change. Thus, 






effective therapeutic approach to treat AD. 
2.6 Aim of the work 
In order to identify small molecules, which increase cellular Aβ clearance, the first aim of 
this work was to model the phenomenon of intracellularly accumulating Aβ42 aggregates, 
which are taken up from the extracellular space and accumulate within multivesicular 
bodies of the endolysosomal pathway. The cell model system should be intensively 
characterized for its Aβ42 aggregate uptake mechanism, the localization and biochemical 
properties of accumulating Aβ42 aggregates to evaluate its potential and suitability as a 
disease model for AD pathology. 
In a next step, the model system clearly exhibiting major characteristics of in vivo 
pathology should be scaled up to a high-throughput capable, cell-based screening assay 
for the identification of small molecules reducing the abundance of endocytotically-
derived intracellular Aβ42 aggregates. In a proof-of-principle approach it was the aim to 
show that this assay is able to identify compounds, which lead to a significant reduction 
of intracellularly accumulating Aβ42 aggregates. 
Then, the cellular Aβ42 aggregate reductive effect of the most potent hit compound 
should be validated using independent biochemical readouts and its concentration-
dependent effect should be evaluated in titration experiments. Further, the aim was to 
assess, whether the compound-mediated cellular Aβ42 reduction was able to ameliorate 
Aβ42’s seeding activity and whether compound treatment does in fact counteract Aβ42-
induced toxicity in neuronal cells. 
Next, it was the aim to elucidate the mechanism of how the compound-mediated reduction 
of the cellular Aβ42 aggregate load is mediated and whether the direct modulation of 
Aβ42 aggregate formation and the compounds’ remodeling propensity accounts for 
increased cellular Aβ42 clearance. 
Finally, it should be resolved, whether structural remodeling of Aβ42 aggregates through 
EGCG is responsible for the increased Aβ42 degradation through lysosomal enzymes – 
providing a potential mechanistic explanation for the strong, cellular Aβ42 aggregate 
degradation promoting effect of direct amyloid-targeting polyphenols.  
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3 Material and Methods 
3.1 Aβ42 peptide stock solutions 
Synthetic Aβ42 peptides produced via solid-state peptide synthesis were dissolved in 
(1,1,1,3,3,3)-Hexafluoroisopropanol (HFIP) overnight, sonicated for 30 min, aliquoted and 
lyophilized with a vacuum concentrator. Monomeric Aβ solutions (200 µM) were prepared 
from HFIP treated peptides by dissolution of the lyophilized peptide in 10 mM NaOH, 
water bath sonication for 5 min and subsequent dilution in low salt buffer (LSB) to desired 
assay concentrations. Lyophilization and handling of Aβ42 solutions was performed in 
Protein Lobind tubes to minimize binding of peptides to plastic surfaces. 
3.2 Preparation and fluorescent labeling of Aβ42 aggregates 
Aβ42 aggregates were prepared from 20 µM peptide stock solutions by incubation in LSB 
at 37°C for 18 h under constant agitation (300 rpm). For fluorescent labeling of Aβ42 
aggregates, 20 µM Aβ42 peptide stock solutions diluted in LSB were mixed with 5% Aβ42 
peptides which have been N-terminally labeled with the fluorophore 5-Carboxytetra-
methylrhodamine (TAMRA) in solid-state peptide synthesis. Then, mixed Aβ42 peptide 
solutions were likewise aggregated at 37°C for 18 h under constant agitation (300 rpm). 
For cellular uptake experiments, aggregation products were additionally tip sonicated at 
lowest intensity for 1 min. 
3.3 Atomic Force Microscopy (AFM) 
Sheet mica was glued to conventional microscope slides and 20 µl sample solution was 
adsorbed for 15 min onto the freshly cleaved mica, washed with filtered, deionized water 
(5 × 40 μl) and dried overnight. As controls, only aggregation buffer was added to the 
mica slide. Sample images were recorded with a digital multimode NanoWizard II atomic 
force microscope using a cantilever with a resonance frequency f0 of 75 kHz (Bruker AFM 
Probes) in intermittent contact mode. 
3.4 Fluorescence polarization-based Aβ42 aggregation assay 
N-terminally 5-Carboxyfluorescein (FAM) -labeled Aβ42 peptide was dissolved in 1 mM 
NaOH to 50 µM and stored as a stock solution at -20°C (Aβ42-FAM tracer). In Aβ42 
aggregate reactions 0.05 µM Aβ42-FAM tracer was combined with 10 µM unlabeled Aβ42 
peptides in low salt buffer. For seeded aggregation reactions 80 nM (monomer equivalent) 
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preformed Aβ42 aggregates were added as seeds. The aggregation mixtures were 
replenished with LSB to a total volume of 40 µl/well. Fluorescence polarization was 
measured every 15 min at 37 °C in a fluorescence plate reader with a polarization module 
(M1000/M1000 PRO, Tecan) at an excitation wavelength of 470 ± 5 nm and an emission 
wavelength of 528 ± 20 nm in 384 well plates with 5 s shaking before each read. Values 
are means of four technical replicates. Polarization values are calculated as 
dimensionless millipolarization units (mP) with the plate reader software i-control (Tecan). 
3.5 Neuroblastoma cell culture and treatment with Aβ42(-TAMRA) aggregates 
Neuroblastoma SH-EP cells (RRID: CVCL_0524) were cultured in Dulbecco’s modified 
eagle medium (DMEM) containing 10% FCS, 25 mM D-Glucose, 100 units/ml penicillin 
and streptomycin, respectively. Incubation was carried out at 37°C with 5% (v/v) CO2. For 
Aβ42 aggregate internalization, cells were treated with 0.6 or 1 µM unlabelled or Aβ42-
TAMRA aggregates which were directly infused into the cell culture medium. 
3.6 Preparation of cell lysates for biochemical analysis 
Cell lysates for biochemical analysis were prepared as follows: 2.2 x 106 SH-EP cells 
were seeded into T25 cell culture flasks. After adhesion overnight, cells were treated with 
Aβ42-TAMRA aggregates, directly infused into the cell culture medium, as described 
above for indicated timeframes. Then, cells were washed with PBS, trypsinized and 
collected in fresh medium. For compound validation experiments, cells were incubated 
with aggregates for 6 h, washed and trypsinized, before being seeded into 6-well cell 
culture plates on EGCG or dimethyl sulfoxide (DMSO) dilutions. After compound 
incubation for 20 h, cells were collected in fresh medium, transferred to Protein Lobind 
tubes and centrifuged for 3 min at 150 g in a microcentrifuge. After an additional washing 
step in PBS, cell pellets were lysed with 150 µl cell lysis buffer and incubated for 30 min 
at 4°C. Protein concentrations of resulted cell lysates were determined using a 
bicinchoninic acid protein assay kit and were subsequently stored at -80°C before being 
analyzed. 
3.7 Polyacrylamide gel electrophoresis and Western blotting 
For analysis of samples using polyacrylamide gel electrophoresis (PAGE), 20 µg protein 
from cell lysate was added to LDS sample buffer before being boiled for 5 min at 95°C in 
Protein Lobind tubes in a microcentrifuge tube incubator. Then, samples were loaded 
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onto SDS-PAGE gels along with pre-stained protein standard. After electrophoresis for 
35 mins at 200 V with 2-(N-morpholino)ethanesulfonic acid (MES) running buffer, 
separated protein from cell lysates was wet blotted onto a nitrocellulose membrane in 
transfer buffer. Membranes were blocked with 3% milk powder in PBS-T for 1 h at room 
temperature (RT). Then, membranes were incubated with primary antibodies in blocking 
solution overnight at 4°C, followed by washing in PBS-T and subsequent incubation with 
horseradish peroxidase (HRP)-conjugated secondary antibodies for an additional hour at 
RT. Before being visualized, membranes were washed twice with PBS-T and once in 
PBS. For detection, HRP substrate was added and chemiluminescence was measured 
in a LAS-3000 Imaging System. Quantification analysis were performed using ImageJ 
software and intensities were normalized to loading control. 
3.8 Native and denaturing filter retardation assays 
For analysis of insoluble Aβ42 aggregates in denaturing filter retardation assays 
(detection of SDS-stable aggregates), samples were prepared by adding them to an equal 
volume of 4% sodium dodecyl sulfate (SDS) and 100 mM dithiothreitol (DTT) followed by 
boiling samples at 98°C for 5 min. For analysis of Aβ42 aggregates under non-denaturing 
conditions in a native filter retardation assay (detection of Nonidet P-40 (NP40) stable 
aggregates), samples were mixed with an equal volume of 1% NP40 solution. Then, 
detergent (SDS or NP40) treated samples were filtered through a cellulose acetate 
membrane with 0.2 µm pore diameter size in a custom-made filter apparatus. Membranes 
were blocked in blocking solution for 1 h at RT. Aβ42 aggregates retained on the filter 
membrane were then detected using the 6E10 antibody (1:2000) and an anti-mouse 
HRP-conjugated secondary antibody. In case of TAMRA-labeled Aβ42 aggregates, 
additional detection of the fluorescent signal intensities on the filter membrane by exciting 
with a green light source (520 nm) and detecting with a long-pass emission filter (>575 
nm) in a LAS-3000 Imaging System (Fujifilm) was performed. Signal intensities were 
quantified from technical triplicates after background subtraction using Aida Image 
Analyzer Software. 
3.9 Automated fluorescence microscopy and quantification of aggregates in 
cells 
Cells were treated with Aβ42-TAMRA aggregates as described above for indicated times. 
To ensure removal of non-incorporated and surface-bound aggregates, Aβ42 containing 
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medium was aspirated, cells were washed with PBS, trypsinized and collected in fresh 
medium. Then, cells were seeded into 96-well cell culture plates at an initial density of 
4.5 x 104 cells per cm2. After adhesion for at least 3 h, cells were fixed in 2% 
paraformaldehyde (PFA) for 20 mins at RT, followed by nuclei staining with Hoechst 
(1:2500). Cells were then washed twice with phosphate-buffered saline (PBS) before 
fluorescent microscopy was performed in a high-content screening system (HCS) using 
an objective with 20-fold magnification. After image acquisition, automated data analysis 
was performed using HCS Software. For quantification, individual cells were detected 
from Hoechst fluorescent signals (excitation (Ex)/emission (Em) 353/483 nm) and total 
TAMRA fluorescent areas per cell (Ex/Em 555/580 nm) were measured and calculated 
from technical triplicates. To assess the suitability of the cell-based Aβ42 degradation 
assay for high-throughput screening, we determined it’s z-factor (Zhang et al., 1999). 
DMSO treated samples served as negative and EGCG treated samples as positive 
control. The z-factor was then determined from formula (1).  
𝑧 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −
3 (𝜎𝑝 + 𝜎𝑛)
| 𝜇𝑝 − 𝜇𝑛 |
= 1 −
3 (3.6 + 6.5)
| 44.2 − 100 |
= 0.47   (1) 
3.10 Immunofluorescence microscopy and staining of cells with dyes 
SH-EP cells were washed with PBS and fixed with 2% PFA for 20 min at RT. Then, 
Hoechst staining (1:2500) followed by permeabilization with 0.1% Triton X-100 in PBS 
and blocking with 1% bovine serum albumin (BSA) in PBS-T was performed. For 
immunofluorescence staining, cells were incubated with primary antibodies overnight at 
4°C or for 2 hr at 37°C, washed with PBS-T and subsequently stained with secondary 
antibodies for 1 h at RT and washed with PBS before being visualized. Lipid rafts were 
stained with 10 mg/ml of the monosialotetrahexosylganglioside (GM1)-binding, 
fluorescein isothiocyanate (FITC) conjugated cholera toxin subunit B (FITC-CTB) and 
incubated for 1 h at RT. Staining of β-sheet-rich intracellular aggregates was performed 
with 10 µg/ml of the amyloid-binding compound Thioflavin S (ThS) for 10 min at RT. 
3.11 Confocal microscopy 
For confocal microscopy, 9.0 x 104 SH-EP cells per well were seeded on fibronectin-
coated (1:100) cover slips in 24-well cell culture plates. After fixation and fluorescent 
staining was performed (see above), cover slips were transferred to conventional 
microscope slides using fluorescence mounting medium before image acquisition with a 
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Leica SP5 confocal microscope was performed (Advanced Light Microscopy Facility, 
MDC). Cells were identified from Hoechst fluorescent signals (Ex/Em 353/483 nm), 
TAMRA, FITC and ThS fluorescent images were acquired at excitation wavelengths of 
Ex/Em 555/580, 490/525 and 384/429 nm, respectively. Co-localization analysis of 
TAMRA and FITC fluorescent puncta was performed using Fiji Software. 
3.12 Screening of a polyphenol compound library 
A compound library containing 20 polyphenol molecules was utilized for the focused 
screen. Compounds were purchased from Sigma-Aldrich. All compounds were at 
analytical grade (> 95% purity or higher) and dissolved in DMSO at 20 mM and stored at 
-20 °C. To test their cellular Aβ42 degradation promoting effect, cells previously treated 
with Aβ42-TAMRA for 6 h as described above were washed with PBS, trypsinized and 
collected accordingly. Then, Aβ42-TAMRA aggregate harboring cells were seeded onto 
10 µM compound dilutions or DMSO only as control and incubated for additional 20 h. 
Automated fluorescent microscopy and data analysis to determine cellular Aβ42 
aggregate loads was performed as described above. 
3.13 Thioflavin T Aβ42 aggregate binding and seeding assay 
For quantification of β-sheet rich aggregates in cells, lysates were prepared as described 
above and 30 µg cell lysate of each sample was transferred to a 384-well plate and 
incubated with 6 µM ThT for 10 min at RT before fluorescence intensities were measured 
(Ex/Em 420/485 nm) in a fluorescence microplate reader (M1000). 
For Aβ42 aggregation kinetics in vitro, 20 µM Aβ42 peptide solutions were prepared as 
described above and mixed with equimolar amounts of ThT in a 384-well plate. For 
compound studies, additional equimolar amounts of EGCG, derivatives or DMSO as 
control were added to in vitro Aβ42 aggregation reactions (total volume 40 µl). Then, 
fluorescence intensities (Ex/Em 420/485 nm) were measured every 20 mins in a 
fluorescence microplate reader (M1000). 
To evaluate seeding-activity of intracellular Aβ42 aggregates, cells were first 
mechanically lysed in a tissue homogenizer. Protein concentrations were then 
determined using the BCA assay and 1 µg of cell lysate was added to in vitro Aβ42 
aggregation reactions monitored from ThT fluorescence intensities over time as 
described above. For quantification of seeding-activity, aggregation kinetics were non-
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linearly fitted and time-points at which the half maximal ThT signal intensity was reached 
(t50) were calculated using GraphPad PRISM Software. Then, the t50 value of treated 
samples was subtracted from control samples’ t50 values resulting in a value for seeding-
activity (∆ t50 (h)), which resembles the acceleration or deceleration of spontaneous Aβ42 
aggregation. 
3.14 Preparation of neuronal primary cultures from rat hippocampi 
Animal tissue preparation and neuronal cell isolation was performed by Dr. Aline Schulz 
(AG Meier, Max Delbrück Center for Molecular Medicine). All animals were sacrificed 
according to the permit given by the Office for Health Protection and Technical Safety of 
the regional government of Berlin (LaGeSo, T0122/07, to Prof. Jochen Maier) and in 
compliance with regulations laid down in the European Community Council Directive. Cell 
culture plates were coated with 0.005% poly-DL ornithine hydrobromide in H2O at 37°C 
overnight and further incubated with DMEM containing 10% FCS for several hours. The 
pregnant rats were sacrificed by cervical dislocation, embryos were dissected and moved 
into ice-cold standard salt solution (SSS). The brains of each embryo were isolated and 
collected in ice-cold SSS. Then, meninges of brains were removed, and hippocampi were 
isolated. Hippocampal tissue was cut into small pieces and treated with trypsin solution 
for 5 mins at 37°C. Trypsinization was stopped with DNase-Ovomucoid solution. To 
singularize cells, tissue was grinded, cells were counted and plated at an initial density of 
6.8 x 104 cells per cm2 in coated 96-well cell culture plates. Hippocampal neuron cultures 
were sustained in 2% B27- and 1% FCS-supplemented neurobasal medium containing 
25 µM ß-mercaptoethanol, 0.25 mM L-glutamine and 0.05% Penicillin/Streptomycin 
(Brewer et al., 1989). To eliminate glia cells from the culture, cells were treated with 5 µM 
cytarabine (AraC) on day in vitro two. 
3.15 Mitochondrial metabolic rate assay (MTT) 
For analysis of SH-EP cell mitochondrial metabolic rate, neuroblastoma cells were 
cultured as described and seeded at an initial density of 2.0 x 104 cells per well into 96-
well cell culture plates. In case of mitochondrial metabolic analysis in neurons, primary 
rat hippocampal neurons were prepared as described above. Neuroblastoma cells or 
primary neurons were treated with 1 µM preformed Aβ42 aggregates or aggregation 
buffer as control. Then, cells were treated with indicated EGCG concentrations and 
further incubated for 24 h. To evaluate cell viability, cells were treated with MTT (3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent and incubated for 
additional 4 h at 37°C. Then, stop solution was applied, incubated for 1 h and absorbance 
at 570 nm was measured in a fluorescence microplate reader (M200).  
3.16 Mouse embryonal fibroblast (MEF) cell culture 
Wild-type (autophagy related 5 protein (ATG5) +/+) and ATG5 knockout (ATG5 -/-) MEFs 
were cultured in DMEM containing 10% FCS, 25 mM D-Glucose, 100 units/ml penicillin 
and streptomycin, respectively. Incubation was carried out at 37°C with 5% (v/v) CO2. For 
Aβ42-TAMRA aggregate internalization, 0.6 µM of aggregate solution was directly 
infused into the cell culture medium. After Aβ42 aggregate uptake, cells were trypsinized, 
washed and transferred to 96-well cell culture plates onto compound dilutions as 
described above. Immunofluorescence staining was performed as described above. 
Aggregate loads were quantified using automated fluorescence microscopy. 
3.17 Cathepsin B enzyme activity assay 
SH-EP cells were cultivated and treated with Aβ42-TAMRA aggregates as described 
above. Then, cells were washed, trypsinized, collected in fresh medium and 90 x 104 cells 
were seeded onto EGCG or DMSO as control in 6-well cell culture plates. After incubation 
for 18 h, medium was aspirated, cells were washed in PBS, mechanically detached from 
the surface and collected in Protein Lobind tubes. After centrifugation for 3 min at 150 g, 
supernatant was removed and 100 µl M2 lysis buffer was added to cell pellets. After lysis 
for 30 mins at 4°C, protein concentrations were determined using a BCA assay kit and all 
samples were adjusted to total protein concentration of 1 µg/µl in M2 lysis buffer. Then, 
25 µg lysate was added to 50 µM of the cathepsin B (CatB) substrate Z-Arg-Arg-7-amido-
4-methylcoumarin hydrochloride (Z-RR-AMC) diluted in cell free system buffer and 
incubated for 1 h at 37°C. AMC fluorescence intensities were measured using a 
fluorescence microplate reader (M200). 
3.18 EGCG derivative library 
EGCG derivatives commercially available were purchased from Sigma-Aldrich. (+)-EGC, 
EGC-3,5-DHB, EGC-3,4-DHB, EGC-3-FB, EGC-4-FB, EGC-4-HB, EGC-Biotin, 
Rhodamine B Linker and EGC-Rhodamine B were custom synthesized, identity checked 
by nuclear magnetic resonance (NMR) spectroscopy and kindly provided by collaborators 
at the Heinrich-Heine University Düsseldorf (Angelika Motzny, Prof. Dr. Constantin 
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Czekelius). All compounds were at analytical grade (> 95% purity or higher) and dissolved 
in DMSO to 20 mM or 60 mM and stored at -20°C or -80°C. To test their cellular Aβ42 
degradation promoting effect, Aβ42 in cell degradation assay was performed as 
described above. In vitro aggregation inhibiting effects were assessed in ThT aggregation 
kinetics (see above for experimental details).  
3.19 Co-localization studies of EGCG and intracellular Aβ42 aggregates 
SH-EP cells were treated with 0.6 or 1 µM preformed Aβ42-TAMRA or Aβ42-HiLyte 
aggregates for 6 h as described above. After trypsinization and washing to remove 
extracellular and surface-bound aggregates, 9.0 x 104 cells per well were seeded onto 
fibronectin (1:100) and poly-L-lysine (1:100) coated cover slips in 24-well cell culture 
plates. Then, cells were treated with 30 µM of biotin- or rhodamine B-labeled EGCG 
derivatives (EGCG #25, #44) and DMSO or rhodamine B with the linker only (EGCG-
control #37) as control. After 3 h of incubation, SH-EP cells were fixed in 2% PFA and 
prepared for confocal microscopy as described above. In case of the biotin-labeled EGCG 
derivative, cells were fixed, blocked in 1% BSA, permeabilized with 1% Triton-X and 
additionally stained with Streptavidin-Cy5.  
3.20 EGCG-mediated remodeling of Aβ42 aggregates 
20 µM Aβ42 peptides were preaggregated as described above (in LSB, 37°C, 300 rpm, 
18 h). For remodeling, two approaches where chosen: EGCG-aggregation samples were 
aggregated in presence of three-fold molar excess of EGCG (20 µM Aβ42: 60 µM EGCG), 
in EGCG-disaggregation samples preformed Aβ42 aggregates (18 h) were incubated for 
an additional 24 h in the presence of a three-fold excess of EGCG. Then, EGCG-
aggregation and -disaggregation samples were analyzed for changes in morphology and 
size distribution of aggregates by AFM and transmission electron microscopy. 
3.21 Transmission electron microscopy (TEM) 
Samples were diluted to 2 µM (monomeric concentration) in LSB. Then, 5 µl of sample 
solution was adsorbed to carbon-coated copper grids for 1 min. Residual buffer was 
removed with filter paper and the grid was negatively stained with 5% uranyl acetate. 
Images were acquired in a Philips CM-100 transmission electron microscope. 
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3.22 Density gradient centrifugation 
Native and EGCG-remodeled Aβ42 aggregates were subjected to iodixanol gradient 
centrifugation. The assay principle was published by Brener O. et al. naming the method 
quantitative determination of interference with Aβ aggregate size distribution (QIAD) 
(Brener et al., 2015). The published protocol was slightly adapted to analyze the EGCG-
mediated remodeling effect. Therefore, a discontinuous gradient of iodixanol was 
prepared in an 11 x 34 mm polyallomer ultracentrifuge tube, from bottom to surface: 130 
µl of 50%, 130 µl of 40%, 130 µl of 30%, 390 µl of 20%, 130 µl of 10% and 50 µl of 5% 
(w/v) iodixanol. Then the gradient was overlaid by 50 µl of the analyzed Aβ42 aggregate 
sample solution. Ultracentrifugation was performed at 4°C with a TLA-55 rotor at 55.000 
rpm for 3 h. After centrifugation, 14 fractions of 70 µl were harvested by upward 
displacement and pellet (~30 µl) was collected as 15th fraction. All fractions were 
denatured with 2% SDS and 50 mM DTT and boiled at 95°C for 5 mins. Then fractions 
were analyzed for Aβ content in dot blot assays using the 6E10 antibody. 
3.23 In vitro Cathepsin B activity and cleavage of Aβ42 aggregates 
For in vitro CatB activity and cleavage studies of native and remodeled Aβ42 aggregates, 
CatB purified from human liver was purchased (Enzo Life Sciences), aliquoted at stock 
concentration of 437 µg/ml and stored at -80°C. For analysis of direct compound effects 
on enzyme activity in vitro, CatB was prediluted to 100 µg/ml in H2O containing 0.1% Brij-
35 and 4 mM L-Cysteine for enzyme preactivation, which was carried out for 5 min at RT. 
Next, fluorescent cathepsin substrate Z-R-R-AMC was diluted in cathepsin in vitro assay 
buffer to 10 µM. Preactivated enzyme was added to substrate solution at a final 
concentration of 1 µg/ml. Then, 10 µM EGCG, CatB inhibitor CA074 or DMSO as control 
were added to enzyme-substrate mixtures. Samples were transferred to a 384-well plate 
and AMC fluorescence intensity was measured in triplicates over time in a fluorescence 
microplate reader (M1000, Em/Ex: 348/440 nm). For in vitro CatB cleavage of Aβ42 
aggregates, morphology and size distribution of EGCG-induced, remodeled Aβ42 
aggregates were analyzed using AFM, TEM and gradient centrifugation. Native and 
remodeled aggregate species were then digested with CatB and analyzed for cleavage 
efficiency. Therefore, 5 µg/ml preactivated CatB or enzyme buffer as control was added 
to 10 µM Aβ42 aggregate solutions and incubated for 4 h at 37°C. Digestion reactions 
were stopped with 1x protease inhibitor (PI) cocktail and phenylmethylsulfonyl fluoride 
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(PMSF). Samples were analyzed in dot blot and filter retardation assays using 6E10 and 
SySy28703 Aβ-detecting antibodies. 
3.24 Material and equipment 






























































































Table 2. List of recombinant proteins and peptides 
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Table 3. List of antibodies 
























Mouse, monoclonal 1:1000 abcam 
anti-EEA1 Early endosome 
antigen 1 








Mouse, monoclonal 1:1000 Invitrogen 
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Table 4. List of dyes, fluorophores and substrates 
Dye / fluorophore Abbreviation Ex / Em (nm) 
▲ 
Provider 
Z-Arg-Arg 7-amido-4-methylcoumarin Z-R-R-AMC 348 / 440 Sigma-Aldrich 
Hoechst 33342 Hoechst 353 / 483 Life Technologies 
Thioflavin S ThS 384 / 429 Sigma Aldrich 
Thioflavin T ThT 440 / 485  Sigma-Aldrich 
FITC-Cholera toxin B FITC-CTB 490 / 525 Sigma-Aldrich 
5-Carboxyfluorescein FAM 494 / 521 AnaSpec 
Alexa Fluor™ 488 Alex488 498 / 520 ThermoFisher 
HiLyte Fluor™ 488 HiLyte 501 / 527 AnaSpec 
Lysotracker™ Green Lysotracker 504 / 511 Sigma-Aldrich 
Carboxy tetramethyl-rhodamine TAMRA 555 / 580 Bachem 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
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Table 5. Laboratory kits, chemicals and stock solutions 
Description ▲ Substance / Product Manufacturer / Provider 
Antibiotic-Antimycotic (AΒ-AM) Penicillin, Streptomycin, Amphotericin B Gibco 
B27 B-27™ Supplement Gibco 
BCA assay kit PierceTM BCA Protein Assay Kit ThermoFisher Scientific 
Benzonase® Endonuclease from Serratia marcescens Merck Millipore 
Brij-35 Brij™-35, 30% solution Sigma-Aldrich 
Cytochalasin D Cytochalasin D, C8273 Sigma-Aldrich 
D-Glucose Glucose solution Gibco 
DMEM various Gibco 
EIPA 5-(N-ethyl-N-isopropyl) amiloride, A3085 Sigma-Aldrich 
FCS Fetal calf (bovine) serum Gibco 
Fibronectin Fibronectin from bovine plasma Gibco 
HFIP 1,1,1,3,3,3-Hexafluoro-2-propanol Sigma-Aldrich 
HRP substrate Pierce ECL Western Blotting Substrate Thermo Fisher Scientific 
Iodixanol OptiPrep™ Density Gradient Medium Sigma-Aldrich 
L-Cysteine (R)-2-Amino-3-mercaptopropionic acid Sigma-Aldrich 
LDS sample buffer NuPAGE LDS sample buffer (4x) Invitrogen 
Milk powder Low-fat powdered milk Carl Roth 
Mounting medium Dako S3032 Agilent / Dako 
Penicillin and Streptomycin Penicillin-Streptomycin Gibco 
PMSF Phenylmethylsulfonyl fluoride Roche 
Protease inhibitor cocktail cOmplete™, EDTA-free Roche 
Protein ladder SeeBlue Plus2 Thermo Fisher Scientific 
SDS Sodium dodecyl sulfate Sigma-Aldrich 
Triton™ X-100 polyethylene glycol tert-octylphenyl ether Sigma-Aldrich 
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Table 6. List of buffer solutions 
Buffer solution (abbr.) Ingredient Final 
concentration 
Purpose ▲ 
Low salt buffer (LSB) 








Cell free system buffer 
pH = 7.4 























CatB activity in cells 
Cathepsin in vitro assay buffer 







CatB in vitro assay 
Cell lysis buffer 
















1.0 x    
Cell lysis for analysis 
of intracellular Aβ42 
aggregates 
M2 lysis buffer 
pH = 7.4 
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PMSF 0.1 mM 
Phosphate buffered saline (PBS) 
pH = 7.4 
 
 












MES SDS running buffer 










Standard salt solution (SSS) 
pH = 7.4 
NaCl 
KCl 
CaCl2 x 2*H2O 
MgCl2 x 6*H2O 

































pH = 7.4 
Hank’s MEM 
MgCl2 x 6*H2O 
HEPES 
D-Glucose 












Transfer buffer (TB-wet) 






10.0 %         
Western Blot (wet) 
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Table 7. Plate types and specifications 
Application ▲ Plate format Provider Description Ref.# 
Aβ42 aggregation in vitro (ThT), 
ThT cell lysate measurements 
384-well BD Falcon Black, clear bottom 353962 
BCA Assay 
 
96-well Nunc Clear, polystyrene P7366 
Cell-based screening assay 
 
96-well BD Falcon Black, clear bottom, 
tissue culture 
353219 
Cover slip sample preparation for 
confocal microscopy 
24-well Greiner CELLSTAR® 
clear 
662160 
Table 8. List of laboratory instruments and equipment 
Instrument ▲ Model Provider 
AFM NanoWizard® II JPK Instruments 
AFM Mica Agar mica NanoWorld AG 
Cellulose acetate membrane OE66 Schleicher and Schuell 
Centrifuge Allegra X-12 Beckman Coulter 
CO2 incubator CB 160 Binder 
Confocal microscope TCS SP5 Leica 
Electrophoresis system XCell SureLock™ ThermoFisher Scientific 
Filter assay unit Hybrid manifold Life Technologies 
Fluorescence microplate reader M200 Tecan 
Fluorescence microplate reader M1000 Tecan 
High-content array scanner Cellomics™ ArrayScan VTI HCS  ThermoFisher Scientific 
Imaging System LAS-3000 Fujifilm 
Light microscope  Axio Imager Zeiss 
Microcentrifuge tube incubator Thermomixer Eppendorf AG 
Nitrocellulose membrane BA85 0.45 µm Protran / Whatman 
Protein low-binding tubes  Protein Lobind Eppendorf 
SDS-PAGE Gels NuPAGE Bis-Tris (1 mm, 4-12%) Invitrogen 
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Semi-dry blotting unit Trans-Blot® SD Semi-Dry Transfer Cell BioRad 
TEM CM-100 Philips 
TEM copper grid „Glimmer“ V3, G250-2 PLANO GmbH 
Tip sonicator Ultrasonicator 450 Branson 
Tissue homogenizer Precellys 24 Bertin Instruments, USA 
Ultracentrifuge TL 100 Beckman Coulter 
Ultracentrifuge tubes Polyallomer tubes, #357448 Beckmann Coulter 
Vacuum concentrator SpeedVac Plus SC110A Savant 
Water bath sonicator SONOREX Digitec Bandelin 
Wet blotting unit Mini Trans-Blot® Cell BioRad 
Table 9. List of Software used 
Software ▲ Application Provider Version 
AIDA Image Analyzer Dot blot and filter 
retardation assay 
analysis 
Elysia-raytest GmbH 3.21 









(Fiji – “Fiji is just 
ImageJ”) 










4.1 Fluorescent labeling and characterization of preformed Aβ42 aggregates 
To establish a cell-based screening assay which is high-throughput capable and not 
dependent on antibody staining for the detection of intracellular Aβ42 aggregate load, 
fluorescently labeled Aβ42 aggregates were prepared from in vitro aggregation reactions. 
Therefore, synthesized Aβ42 peptides were used, which were N-terminally labeled with 
the fluorophore 5-Carboxytetramethylrhodamine (TAMRA). TAMRA-labeled Aβ42 
peptides were incorporated into Aβ42 aggregates by mixing 5% of fluorescently-labeled 
Figure 2. Characterization of preformed Aβ42 aggregates. (A) Atomic force microscopy 
of TAMRA- and unlabeled Aβ42 aggregates showing similar aggregate morphology and 
fibril heights. 10 µM Aβ42 peptides where incubated for 18 h at 37°C. Scale bars: 300 
nm. (B) Characteristic fluorescence spectrum shift of ThT upon Aβ42 aggregate binding 
indicates high β-sheet content. Aβ42 monomers show no ThT binding capacity. Aβ42:ThT 
ratio, 1:1; 10 µM. (C) Biochemical analysis of preformed Aβ42 aggregates. SDS-stability 
was assessed in denaturing filter retardation assays. Signals were detected from TAMRA 
or 6E10 antibody signals. (D) Quantification of SDS-stable Aβ42 aggregates in C. (E) 
Seeding activity of labeled and unlabeled Aβ42 aggregates. Aβ42-TAMRA aggregates 
are seeding competent in Aβ42 fluorescence polarization assay. Bars represent means 







with 95% unlabeled peptides and incubation of mixed Aβ42 peptide solutions for 18 h 
under constant agitation in low salt buffer (LSB). As smaller particles with an increased 
overall surface are potentially more efficiently internalized, resulting aggregation products 
were additionally sonicated after incubation. TAMRA-labeled Aβ42 aggregate species 
were analyzed in atomic force microscopy and it was investigated whether fluorescent 
labeling results in changes on aggregate morphology. Fluorescently labeled aggregates 
were similar in morphology and fibril heights compared to unlabeled Aβ42 aggregates 
when analyzed by AFM (Figure 2, A). Resulting aggregate species were further 
characterized by analyzing their ThT binding properties. Binding of ThT to β-sheet-rich 
amyloid structures typically results in a characteristic shift of its fluorescence spectrum 
(Biancalana and Koide, 2010) and is widely used to stain for Aβ42 pathology in AD model 
systems and patient brain material (Luna-Muñoz et al., 2008). As expected, when 
monomeric Aβ42 peptides were stained, ThT did not shift its spectrum, but for aggregated 
Aβ42 species a typical fluorescence shift could be detected. This was observed for 
unlabeled as well as fluorescently labeled Aβ42 aggregates (Figure 2, B). The slightly 
reduced fluorescent signal of ThT bound to TAMRA-labeled Aβ42 aggregates is 
potentially due to partial absorption of ThT fluorescence by the TAMRA fluorophores. The 
Aβ42 aggregate species found in patient tissue are typically detergent-resistant and are 
in parts not solubilized by SDS treatment (Masters and Selkoe, 2012). Therefore, the 
preformed Aβ42 aggregates were analyzed in filter retardation assays under denaturing 
conditions (2% SDS). In vitro prepared Aβ42 aggregates contained SDS-resistant 
aggregate species, which could be detected with the Aβ42-antibody 6E10 (Figure 2, C). 
Additionally, high-ordered structures retained on the filter membrane showed strong 
TAMRA-fluorescence, indicating that Aβ42-TAMRA peptides are successfully 
incorporated into SDS-stable Aβ42 aggregates (Figure 2, D). Taken together, the 
structural and biochemical characterization of preformed, TAMRA-labeled Aβ42 
aggregates shows that in vitro prepared Aβ42 aggregates exhibit major characteristic 






4.2 Aβ42 aggregates are rapidly internalized by SH-EP cells and are directed 
towards the endolysosomal pathway 
In order to establish a cell-based aggregation degradation assay for compound testing, it 
was next examined, whether SH-EP neuroblastoma cells take up preformed Aβ42 
aggregates after adding them to the culture medium. Therefore, unlabeled and TAMRA-
labeled aggregates were used, which were produced and characterized as stated above 
(Figure 2). To test whether monomeric or aggregated Aβ42 species are preferentially 
internalized by SH-EP cells, Aβ42 aggregates, soluble Aβ42 peptides or aggregation 
buffer alone as a control were added to the cell culture medium. After 6 h, cells were 
Figure 3. Biochemical analysis of SH-EP cell lysates after treatment with Aβ42 
aggregates. (A) Western blot from SH-EP cell lysates treated with Aβ42 aggregates, 
Aβ42 monomer or aggregation buffer only. 6E10 antibody detects SDS-stable aggregates 
in gel pockets as well as an Aβ42 monomer band. APP, its different isoforms, dimers, 
trimers, oligomers and APP fragments are detectable. (B) Native filter retardation assay 
from SH-EP cell lysates treated with Aβ42 aggregates, monomer or buffer as control. 
Only lysates from SH-EP cells treated with preformed Aβ42 aggregates show strong 
aggregate accumulation. No spontaneous formation of Aβ aggregates from endogenous 
APP detectable. Shown are the results from one representative experiment, analysis was 






lysed, and cell lysates were subsequently analyzed by SDS-PAGE and Western blotting. 
Successful Aβ42 aggregate uptake was evaluated by staining Western blots with the 
6E10 antibody. As the 6E10 antibody, besides reacting to Aβ42 peptides, additionally 
detects endogenous APP, this could serve as a loading control. Only when 
neuroblastoma cells were treated with preformed Aβ42 aggregates, SDS-stable 
aggregate species were detectable in the gel pockets (Figure 3, A). An additional band 
was detectable at the size of monomeric Aβ42 peptide, which presumably resembles the 
product from non-detergent resistant Aβ42 aggregates or soluble, monomeric Aβ42 
peptides. (Figure 3, A). In contrast, when equimolar amounts of monomeric Aβ42 
peptides were added to the cell culture medium, neither aggregates nor Aβ42 monomers 
Figure 4. Aβ42 aggregate internalization and cellular aggregate formation. (A) 
Fluorescence microscopy images show increasing formation of TAMRA-positive puncta 
over time. Scale bar: 20 µm. (B) Quantification of cellular, TAMRA-positive puncta over 
time. For validation, cells where co-stained with Aβ-antibody 6E10. (C) Denaturing (SDS) 
and native (NP40) filter retardation assay analysis of SH-EP lysates after Aβ42-TAMRA 
aggregate internalization for indicated timeframes. Aβ42 aggregates were detected from 
TAMRA fluorescent signals, data was normalized to intensities at 8 h. (D) Thioflavin T 
binding assay from cell lysates with Aβ42 aggregate. With increasing cellular aggregate 
load, TAMRA and Thioflavin T fluorescence intensities increase over time indicating build-
up of β-sheet-rich cellular inclusions. Depicted are means from three individual 






could be detected in the cell lysate. The absence of Aβ42 monomer in the cell lysate from 
treated SH-EP cells is probably due to immediate, efficient degradation of monomeric 
Aβ42 peptides by SH-EP cells or inefficient uptake of the monomeric peptide (Jin et al., 
2016). Native filter retardation assays further confirmed that only aggregate treated cells 
contain Aβ42 aggregates and that there is no aggregate formation over time upon 
monomer treatment in these cells. There was also no spontaneous build-up of 
intracellular Aβ42 aggregates observed in control cells due to endogenous APP cleavage 
or the release of Aβ peptides (Figure 3, B).  
To evaluate the time-dependency of the uptake process, SH-EP cells were treated with 
0.6 µM of Aβ42-TAMRA aggregates; cells were fixed after different incubation intervals, 
and cellular aggregate loads were analyzed performing fluorescence microscopy (Figure 
4, A). To validate whether TAMRA fluorescent puncta in fact consist of Aβ42 aggregates, 
fluorescent puncta per cell were quantified from TAMRA, as well as from 6E10 antibody 
signals after immunofluorescence staining. It was found that, in treated cultures, 
fluorescently labeled and antibody positive puncta are first detectable after 2 h. The 
abundance of these structures increases over time and reaches saturation after 8 h of 
incubation, indicating that Aβ42-TAMRA aggregates are rapidly internalized in a time-
dependent manner (Figure 4, B).  
The observation of fluorescent puncta suggests that intracellular, insoluble Aβ42 
inclusions are formed in SH-EP cells. To confirm that the increase of fluorescent puncta 
detected over time resembles the build-up of intracellular Aβ42 aggregates, cell lysates 
from different time points were analyzed using filter retardation assays. In line with the 
microscopic analysis, increasing Aβ42 aggregate loads could be detected with filter 
retardation assays under native as well as under denaturing conditions, indicating the 
build-up of detergent-soluble and -insoluble cellular Aβ42 aggregates (Figure 4, C). As 
Aβ42 aggregates found in patient material consist of compact β-sheet structures (Masters 
and Selkoe, 2012), it was further analyzed, whether the resulting protein aggregate 
species in SH-EP cells are β-sheet rich by incubating cell lysates with the β-sheet binding 
dye ThT. With increasing intracellular Aβ42 aggregate accumulation, ThT fluorescence 
intensity of cell lysates increased accordingly indicating the build-up of compact, β-sheet-






containing lysates are due to ThT binding to intracellular Aβ42 aggregates, it was further 
analyzed whether Thioflavin directly co-localizes with intracellular Aβ42 aggregates in 
SH-EP cells. For cell culture and tissue stainings of amyloids, ThS instead of ThT is 
typically used (Sun et al., 2002). Therefore, cells with intracellular Aβ42 were fixed, 
stained with ThS and analyzed for co-localization by confocal microscopy. In fact, 
intracellular Aβ42 aggregates in the neuroblastoma cells were highly ThS-positive and 
strongly co-localized with Aβ42-TAMRA aggregates (Figure 5, A). Finally, it was 
analyzed to which cellular compartment intracellular Aβ42 aggregates localize in SH-EP 
cells. In pathological studies it has been observed, that protein aggregates – including 
Aβ42 aggregates – taken up from the extracellular space mainly localize to acidic 
organelles (Hu et al., 2009). Thus, SH-EP cells were stained with the acidic organelle 
accumulating dye Lysotracker. Strong co-localization of Lysotracker fluorescence 
intensity with intracellular Aβ42-TAMRA aggregates was observed by confocal 
microscopy, suggesting distinct localization of Aβ42 aggregates to acidic organelles in 
this model system (Figure 5, B). 
Taken together, treating neuroblastoma cells with in vitro preformed Aβ42 aggregates 
Figure 5. Intracellular Aβ42 aggregates accumulate in acidic organelles. (A) Staining of 
intracellular Aβ42 aggregates shows highly ThS positive puncta. Co-localization analysis 
of ThS and TAMRA signals confirm that TAMRA-labeled Aβ42 aggregates contain β-
sheet-rich amyloid peptide structures. Scale bar: 10 µm. (B) Internalized Aβ42 
aggregates accumulate in acidic organelles. Aggregates strongly co-localize with the 
Lysotracker dye. Scale bar: 5 µm. Showing one representative image and co-localization 







leads to the formation of SDS-stable, ThT-positive intracellular aggregates, which 
accumulate in acidic organelles. These characteristics resemble well the biochemical 
properties and spatial distribution of intracellular Aβ42 aggregates found in AD patients 
(Masters and Selkoe, 2012). Hence, modelling the pathology of intracellular Aβ42 
aggregates in SH-EP cells is a suitable approach to develop a screening assay for the 
identification of small molecules promoting Aβ42 aggregate degradation. 
4.3 Aβ42 aggregates are internalized through actin-dependent, lipid raft-
mediated macropinocytosis 
As compounds potentially identified by this screening assay should especially target 
intracellular Aβ42 aggregates shuttling between neuronal cells, it was investigated, 
whether the cell model internalizes Aβ42 aggregates through in vivo described Aβ42 
internalization pathways. Different mechanisms of Aβ aggregate uptake have been 
described and are discussed. Among these receptor-mediated endocytosis at lipid rafts 
plays a particular important role for neuronal aggregate uptake and cell-to-cell transfer 
(Lai and Mclaurin, 2011). To assess whether lipid raft mediated uptake is involved in this 
neuroblastoma model system, SH-EP cells were treated with Aβ42-TAMRA aggregates, 
fixed after 2 h of incubation and then stained with the ganglioside GM1 binding protein 
cholera toxin B (CTB), which marks lipid rafts on the cell surface (Blank et al., 2007). 
TAMRA fluorescent puncta partly co-localized with FITC-CTB, indicating binding of Aβ42 
aggregates to lipid rafts on the cell surface (Figure 6, A). Partial co-localization of Aβ42 
aggregates with CTB most likely resembles transient binding to lipid rafts throughout the 
uptake process. The receptor mediated, active endocytosis at lipid rafts is a β-actin 
dependent process (Head et al., 2014). To gain further evidence that this process is 
responsible for Aβ42 aggregate uptake in this model system, I tested whether treatment 
with a β-actin polymerization inhibitor prevents Aβ42 aggregate uptake. Therefore, 
neuroblastoma cells were treated with increasing concentrations of the actin-
polymerization inhibitor cytochalasin D prior to Aβ42 aggregate treatment and the 
remaining uptake was evaluated. In a concentration-dependent manner, inhibition of β-
actin polymerization lead to a strong decrease in cellular Aβ42 aggregate loads (Figure 






particular form of endocytosis is involved in SH-EP cells. Macropinocytosis, a form of  
clathrin-independent endocytosis, which mediates non-selective uptake of solute 
molecules and large gulps, is highly active in macrophages and dendritic cells (Bloomfield 
and Kay, 2016). As it has been described to be particularly involved in Aβ42 uptake 
Figure 6. Aβ42 aggregate internalization via lipid-raft mediated macropinocytosis. (A) 
Confocal microscopy shows Aβ42 aggregates partly co-localizing with lipid rafts on the 
cell surface. SH-EP cells were treated with Aβ42-TAMRA aggregates and fixed after 2 h. 
Lipid rafts are stained with the ganglioside GM1 binding subunit B of cholera toxin 
conjugated to FITC. TAMRA and FITC fluorescence intensities were quantified along 
white arrow in the merged image. Fluorescent signals clearly overlap at several locations 
indicating Aβ42 aggregates transiently bind to lipid rafts on the cell surface. 
Representative image shown with co-localization analysis using the Pearson’s correlation 
coefficient. (B) Filter retardation assays of denatured (2 % SDS) lysates from SH-EP cells 
treated with Aβ42 aggregates and increasing concentrations of cytochalasin D (CytD) 
show effective uptake inhibition. TAMRA fluorescence intensities from Aβ42-TAMRA 
aggregates retained on the filter membrane were quantified. (C) Amount of intracellular 
Aβ42-TAMRA aggregates after pretreatment of SH-EP cells with macropinocytosis 
inhibitor EIPA. Internalized Aβ42 aggregate loads were quantified from total TAMRA 
intensities. Depicted are the means from technical triplicates of one representative 
experiment. Error bars representing standard deviation. One-way ANOVA with Dunnett’s 






(Mandrekar et al., 2009) it was investigated whether SH-EP cells take up preformed Aβ42 
aggregates via this distinct pathway. Prior to Aβ42-TAMRA aggregate addition to the cell 
culture media, SH-EP cells were treated with 5-(N-ethyl-N-isopropyl) amiloride (EIPA). 
This agent effectively inhibits macropinocytosis in the micromolar range (Koivusalo et al., 
2010). Consequently, when increasing concentrations of EIPA were applied, an almost 
complete uptake inhibition of Aβ42 aggregates could be observed (Figure 6, C).  
This suggests that SH-EP cells internalize Aβ42 aggregates via β-actin dependent, lipid-
raft-mediated macropinocytosis – an aggregate uptake pathway, especially described to 
be involved in microglia-mediated clearance of Aβ42, which is likely involved in 
propagation and cell-to-cell spreading of Aβ42 aggregates (Zeineddine and Yerbury, 
2015). Therefore, this neuroblastoma cell model system involves an Aβ42 aggregate 
uptake mechanism which is highly relevant in Aβ42 processing in vivo and thus presents 
a suitable cell model system to assess the effects of small molecules in promoting the 
degradation of Aβ42 aggregate species particularly involved in this pathophysiological 
process. 
4.4 A cell-based screening assay facilitates the identification of small 
molecules promoting the clearance of intracellular A aggregates 
Next, this model system was used to identify chemical compounds that influence the 
levels of intracellular A aggregates. Therefore, a cell-based semi-automated screening 
assay was established for compound testing in microtiter plates. The principle of the 
assay is schematically shown in Figure 7 A. First, SH-EP cells are treated with preformed 
Aβ42-TAMRA aggregates to promote the formation of intracellular aggregates. Next, the 
cells are washed and trypsinized to remove non-internalized Aβ42 aggregates from the 
cell culture. The intracellular Aβ42 aggregate harboring cells are then seeded into 
microtiter plates onto 10 µM compound dilutions and are further incubated for 20 h. After 
fixation and cell nuclei staining, remaining Aβ42 aggregate loads per cell are quantified 
using a microscopic high content fluorescence imaging system. 
As a proof-of-principle study, a focused library of 20 polyphenol compounds was tested 
(Figure 7, B), since several compounds of this chemical subgroup have been shown to 
exhibit effects on amyloid-β aggregation in vitro and in vivo (Bieschke, 2013; Stefani and 
Rigacci, 2013). Among these 20 compounds, 5 significantly promoted the degradation of 






intracellular Aβ42 aggregates. Notably, the green tea flavonoid epigallocatechin gallate 
(EGCG) (Figure 7, C), which was previously shown to directly target preformed β-sheet-
rich Aβ42 aggregates and to promote their dissociation in vitro (Bieschke et al., 2010; 
Ehrnhoefer et al., 2008), exhibited the most potent effect. It reduced the intracellular Aβ42 
aggregate load by 56% at a concentration of 10 µM (Figure 7, B, C). Two further 
Figure 7. Cell-based screening assays identifies polyphenols increasing Aβ42 aggregate 
degradation. (A) Schematic representation of the screening assay. SH-EP cells are 
treated with 0.6 µM Aβ42-TAMRA aggregates and incubated for 6 h. Cells are washed, 
trypsinized and transferred to cell-culture plates containing 10 µM compound dilutions. 
After incubation for additional 20 h, cells are fixed, and Aβ42 aggregate loads per cell are 
quantified in a high-content fluorescent imaging system. (B) Results from the focused 
library screen. Aβ42 aggregate loads are quantified from total fluorescent intensities per 
cell and normalized to solvent control (DMSO). (C) Molecular structure of the most potent 
polyphenol – Epigallocatechin gallate (EGCG) – reducing cellular Aβ42 aggregates in 
SH-EP cells by 56 ± 3.6% at a concentration of 10 µM. (D) Summary of the effects of the 
aggregation-modulating compounds on intracellular Aβ42 aggregate levels. 25% of the 
tested compounds showed a significant Aβ42 aggregate reduction. Depicted are the 
means of three individual experiments with error bars representing standard deviation. 






flavonoids were among the hit compounds: Robinetin and Myricetin (Figure 7, B) – two 
naturally occurring polyphenols which previously showed neuroprotective effects in 
cellular model systems of neurodegeneration (Regitz et al., 2014). Moreover, Myricetin 
showed potent inhibition of Aβ fibril formation in vitro (Hirohata et al., 2007) and was 
effective in reducing Aβ pathology aggregates in an AD transgenic mouse model 
(Hamaguchi et al., 2009). Oxytetracycline, an FDA-approved antibiotic and derivative of 
tetracycline, likewise strongly reduced the levels of intracellular Aβ42 aggregates (Figure 
7, B). Notably, this compound has also been shown to inhibit Aβ aggregate formation in 
vitro (Inbar et al., 2008) and was further described to inhibit the interaction of Aβ oligomers 
with ephrin type-B receptor 2 – a receptor tyrosine kinase important for learning and 
memory functions (Suzuki et al., 2016). Additionally, 6-Hydroxy-DL-DOPA, a derivative 
of the Parkinson drug Levodopa (Poskanzer, 1969) showed the second strongest effect 
reducing the abundance of intracellular Aβ42 aggregates by 48%. Interestingly, dopamine 
itself was previously identified in a screen for Aβ binders and aggregation inhibitors in 
vitro (Inbar et al., 2008). Thus, the identified compounds that lead to a reduction of 
intracellular Aβ42 aggregates in cells are either themselves or structurally related to in 
vitro aggregation inhibitors.  
Next, the effects of EGCG on the abundance of intracellular Aβ42 aggregates was 
assessed in independent titration experiments with increasing compound concentrations. 
The Aβ42 decreasing effect was strongly concentration-dependent and a half maximal 
inhibitory compound concentration (IC50) of 6.3 µM was determined (Figure 8, A). To 
validate the reduction of cellular Aβ42 aggregate loads using a different readout, 
additional immunofluorescence stainings with the 6E10 antibody were performed. Similar 
to the reduction of TAMRA fluorescent signals from Aβ42 aggregates, a concentration-
dependent effect on the abundance of intracellular Aβ42 aggregates could be observed. 
However, the effects obtained with the antibody readout were slightly lower compared to 
the TAMRA fluorescent signals, resulting in a 6E10 IC50 of 14.5 µM compared to 6.3 µM 






This discrepancy may result from a quenching effect of EGCG on the TAMRA fluorophore. 
To evaluate this in detail, non-peptide coupled TAMRA fluorophores were incubated with 
increasing concentrations of EGCG. Here, no EGCG-mediated reduction of TAMRA-
fluorescence was observed (Figure 9, A, TAMRA fluorophore). However, there could still 
be an effect of EGCG on the TAMRA-fluorophore when it is incorporated into Aβ42-
TAMRA aggregates as EGCG has been shown to directly bind Aβ42 aggregates in vitro 
(Ehrnhoefer et al., 2008) and thereby might accumulate in close proximity to the 
fluorophores. In fact, when increasing concentrations of EGCG were added to Aβ42-
TAMRA peptides or preformed aggregates in vitro, a strong reduction of TAMRA 
fluorescence intensity of the aggregates could be observed (Figure 9, A). This could 
indeed resemble EGCG-mediated quenching of TAMRA fluorescence upon Aβ42 
aggregate binding or – as EGCG has been shown to remodel Aβ42 aggregates into off-
pathway oligomers (Lopez del Amo et al., 2012) – indicates EGCG-mediated remodeling 
Figure 8. Titration experiment with increasing concentrations of EGCG. (A) Cellular Aβ42 
aggregate loads were determined from total TAMRA fluorescence intensities. Data points 
were non-linearly fitted and an IC50 value was determined at a concentration of 6.3 µM. 
(B) Validation titration experiment; Compound effects were followed by immunofluo-
rescent staining of aggregates with the Aβ-specific antibody 6E10. EGCG-mediated 
promotion of cellular Aβ42 degradation is lower when quantified from antibody signals 
resulting in an IC50 value of 14.5 µM. Depicted data points represent means from three 






of Aβ42-TAMRA aggregates leading to a change in their fluorescence. 
As EGCG apparently reduces TAMRA fluorescence of labeled Aβ42 aggregates itself, 
additional validation experiments were performed to evaluate the Aβ42 aggregate 
degradation promoting effect in the neuroblastoma cell model system. In these 
experiments, the abundance of intracellular Aβ42 aggregates after EGCG treatment were 
additionally analyzed by filter retardation assays. When lysates from EGCG treated SH-
EP cells were filtered through a membrane to quantify cellular aggregates, they likewise 
showed a strong reduction in cellular Aβ42 aggregate loads. This could be observed from 
Aβ-specific antibody signals (4G8) retained on filter membranes as well as when 
measuring the fluorescent intensities of retained TAMRA-labeled aggregate species. 
(Figure 10, A, w/ Aβ42). As control, increasing EGCG concentrations were added to SH-
EP cells, which did not contain intracellular Aβ42 aggregates. Here, the detected 
background signals from cell lysates was not changed – neither from TAMRA nor from 
antibody signals (Figure 10. w/o Aβ42). Taken together, these experiments showed that 
the established assay is suitable for the screening of small molecules, which can promote 
the degradation of preformed intracellular Aβ42 aggregates. With the assay, five 
compounds that significantly decrease the abundance of intracellular Aβ42 aggregates 
Figure 9. Analysis of the effect of EGCG on TAMRA fluorescence. (A) Increasing EGCG 
concentrations were added to non-peptide coupled TAMRA fluorophores, Aβ42-TAMRA 
peptide monomers and labeled Aβ42-TAMRA aggregates in vitro. No reduction of 
TAMRA fluorescent intensity on the dye itself could be detected, whereas EGCG strongly 
reduced TAMRA fluorescent intensities when labeled to Aβ42 peptides or incorporated 






were identified, of which EGCG showed the strongest effect. Furthermore, IC50 values for 
the most potent hit compound EGCG (TAMRA: 6.3 µM; 6E10-antibody: 14.5 µM) were 
determined and the EGCG-mediated effects could be validated using independent 
biochemical readouts. This validation is of critical importance as a direct effect of the 
compound molecule on the assay readout – as TAMRA fluorescence intensity here – 
must be excluded.  
4.5 EGCG-mediated degradation mitigates Aβ42 seeding activity and rescues 
Aβ42-induced toxicity 
As intracellular Aβ42 aggregates might be highly relevant in disease progression and – 
when spreading from cell-to-cell – were shown to seed Aβ aggregation of soluble Aβ 
peptides in pathologically unaffected neuronal cells (Sowade and Jahn, 2017; Ziegler-
Waldkirch et al., 2018), it was evaluated whether an EGCG-mediated decrease of 
intracellular Aβ42 aggregates influences their seeding activity. Therefore, SH-EP cells 
with intracellular Aβ42 aggregates were treated with or without 30 µM EGCG and cell 
extracts where analyzed for their Aβ seeding activity. To exclude that residual EGCG in 
cell extracts and not its degradation promoting effect influences seeding activity, 
additionally non-Aβ42 aggregate containing cells were treated with or without EGCG as 
Figure 10. Validation of EGCG-mediated Aβ42 aggregate degradation. (A) Filter 
retardation assays of native protein extracts (NP40) from SH-EP cells confirm Aβ42 
aggregate degradation promoting effect of EGCG. In the left panel, total TAMRA 
fluorescent intensities are quantified – on the right, cellular Aβ42 aggregates retained on 
filters are detected with the Aβ-specific antibody 4G8. Depicted bars represent means 
from three individual experiments with error bars showing standard deviation. One-way 






a control. After 20 h of compound or solvent control incubation, cells were lysed and the 
cell extracts’ seeding activity was investigated. Therefore, cell extracts were added to in 
vitro Aβ42 aggregation reactions, which were then monitored over time by quantification 
of ThT fluorescence intensities. For quantification of seeding activity, Aβ42 aggregation 
kinetics were non-linearly fitted and time points were calculated, where the half-maximal 
ThT intensity was reached (t50). Seeding activity of cell extracts was quantified from the 
shift of the t50 time point (∆t50) in relation to unseeded aggregation reactions. Expectedly, 
the addition of cell extracts harboring intracellular Aβ42 aggregates exhibited a significant 
seeding effect on spontaneous Aβ42 aggregation in vitro by shortening the lag phase and 
accelerating the aggregation process (+DMSO, Figure 11, A). When extracts from SH-
EP cells treated with 30 µM EGCG (+ EGCG, Figure 11, A) were analyzed with in vitro 
seeding assays, they showed a significantly reduced seeding activity compared to DMSO 
treated samples. In the control experiments, no effect of residual EGCG in cell extracts 
on spontaneous Aβ42 aggregation could be observed (Figure 11, B). 
Whether the reduction of intracellular Aβ42 aggregates or an additional compound-
induced aggregate modification accounts for the observed reduction in seeding activity 
Figure 11. Seeding activity of cell extracts from SH-EP cells with intracellular Aβ42 
aggregates. (A) Addition of cell extracts from SH-EP cells treated with or without 30 µM 
EGCG for 20 h. Intracellular Aβ42 aggregates accelerate spontaneous Aβ42 aggregation, 
whereas treatment with EGCG significantly reduced this seeding effect. Residual EGCG 
from cell extracts (EGCG only) shows no effect on spontaneous Aβ42 aggregation. (B) 
Quantification of seeding activity from the ∆t50 values. Intracellular Aβ42 aggregate 
containing SH-EP cell extracts accelerated spontaneous Aβ42 aggregation by ~ 12 h. 
EGCG treatment reduced this acceleration by ~ 6 h (~ 50%). Bars show mean of one 
representative experiment performed in technical triplicates. Error bars representing 






remains unclear. However, these results clearly demonstrate that treatment of cells 
containing intracellular Aβ42 aggregates with Aβ42 degradation promoting compounds 
such as EGCG, is able to mitigate the cell extracts’ seeding-activity and might therefore 
be a promising approach to impede seeding and spreading of Aβ aggregates. 
Next, it was investigated whether the EGCG-mediated reduction of intracellular Aβ42 
aggregates does rescue Aβ42-induced toxicity. As intracellular, proteotoxic Aβ 
aggregates have been described to compromise physiological cellular functions and to 
decrease mitochondrial metabolism (Liu and Schubert, 2002), the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to examine 
whether EGCG treatment influences mitochondrial metabolic activity of SH-EP cells after 
treatment with Aβ42 aggregates. Addition of 1 µM preformed Aβ42 aggregates to the cell 
culture medium of SH-EP cells did lead to a decline in their mitochondrial metabolic 
activity. However, when cells were treated with increasing concentrations of EGCG, the 
proteotoxic effect of Aβ42 aggregates could be significantly rescued in a concentration-
dependent manner (Figure 12, A). As hippocampal neurons are one of the most affected 
Figure 12. EGCG treatment rescues Aβ42-induced toxicity. (A) Aβ42 aggregate 
treatment affects mitochondrial metabolic activity of SH-EP cells, which can be rescued 
by treating cells with increasing concentrations of EGCG. 1 µM of Aβ42 aggregates added 
to cell culture medium strongly reduce mitochondrial metabolic activity indicated by a 
decreased MTT reduction capacity of the SH-EP cell pool. Treatment with the polyphenol 
EGCG counteracts Aβ42 induced toxicity in a concentration-dependent manner; addition 
of 10 and 20 µM compound significantly improves mitochondrial metabolic activity (B) 
Mitochondrial metabolic activity of rat hippocampal neurons is accordingly impaired when 
neurons are treated with 1 µM of Aβ42 aggregates. Addition of 10 and 20 µM EGCG 
likewise significantly restores metabolic impairment. Bars show mean of three individual 
experiments with error bars representing standard deviation. One-way ANOVA, * p < 






cell populations in patients suffering from AD (West et al., 1994), it was further tested 
whether similar effects of EGCG treatment could be observed with primary neuronal 
cultures prepared from rat hippocampi. Adding in vitro preformed Aβ42 aggregates to the 
cell culture medium resulted in an impairment of neuronal mitochondrial activity (w/ Aβ42, 
Figure 12, B). Notably, when hippocampal neurons were treated with EGCG, Aβ42-
induced toxicity could also be reproducibly rescued in a concentration dependent manner 
(Figure 12, B). 
The results from the seeding and toxicity experiments show that EGCG treatment not 
only decreases the abundance of intracellular Aβ42 aggregates, but is additionally able 
to reduce their cellular seeding-activity and furthermore can rescue Aβ42-mediated 
toxicity by restoring Aβ42-induced mitochondrial impairment. 
4.6 Intracellular Aβ42 aggregates accumulate in lysosomes and the EGCG-
mediated effect is dependent on lysosomal enzyme activity 
As EGCG-mediated reduction of intracellular Aβ42 aggregates seems to be an effective 
approach to reduce their cellular seeding activity and toxicity, it was next investigated how 
this effect is mechanistically exhibited. Therefore, the exact localization of intracellular 
Aβ42 aggregates in SH-EP cells was first analyzed in detail. In vivo, Aβ42 aggregates 
are mainly detected in multivesicular bodies, which include early endosomes, late-
endosomes and lysosomes (Takahashi et al., 2002). To assess the subcellular 
localization of internalized Aβ42 aggregates in SH-EP cells, markers of different cellular 
compartments of the endosomal-lysosomal trafficking pathway and the cellular Aβ 
processing process (Fukuda, 1991) were fluorescently stained and co-localization with 
TAMRA-labeled Aβ42 aggregates was analyzed in confocal microscopy. As it was of 
main interest to elucidate where the intracellular Aβ42 aggregates accumulate, when the 
cells are treated with compounds, their localization was investigated 6 h after aggregate 
addition. In fact, it was found that in neuroblastoma cells at this time point, actively 
internalized Aβ42 aggregates partially co-localized with the early endosome marker EEA1 
(Figure 13, A), but mainly co-localized with the late endosome and lysosome-associated 
membrane protein 2 (LAMP2) (Figure 13, B). Lysosomes have been widely described to 
be the major compartment for degradation of misfolded proteins and protein aggregates 
composed of α-synuclein, huntingtin, tau and Aβ (R.A. Nixon, 2013). This suggests that 






aggregates have already accumulated in the lysosome.  
As autophagy – a major cellular pathway for degradation of misfolded proteins and protein 
aggregates – forms autophagosomes, which subsequently fuse with lysosomes (Menzies 
et al., 2015) and even EGCG itself has been reported to stimulate autophagy (Lee et al., 
2015; Zhou et al., 2014), it was investigated whether the EGCG-mediated effect is 
dependent on autophagic activity. Therefore, a mouse embryonal fibroblast (MEF) cell 
line lacking the ATG5 protein – a key regulator of autophagy (Kishi-Itakura et al., 2014) – 
was used to test, whether the EGCG-mediated effect relies on active autophagy. 
Interestingly, the EGCG-mediated promotion of Aβ42 aggregate degradation was 
reduced in autophagy deficient MEFs in comparison to wildtype cells. EGCG was 
significantly less efficient in promoting intracellular Aβ42 aggregate degradation in ATG5 
knockout cells (Figure 14, A).  
As intracellular Aβ42 aggregates taken up by neuroblastoma cells mainly accumulated in 
lysosomes – the common endpoint of endocytosis and autophagy (Ganley et al., 2011), 
it was further evaluated whether lysosomal enzyme activity is required for the observed 
EGCG-mediated effect on Aβ42 aggregates. Therefore, SH-EP cells were treated with 
Figure 13. Co-localization of internalized Aβ42-TAMRA aggregates with lysosomal 
markers. (A) Co-localization analysis with the early-endosome marker EEA1 shows no or 
only very partial co-localization 6 h after Aβ42 aggregate treatment. (B) Clear co-
localization with the lysosome-associated membrane protein 2 (LAMP2) after 6 h of Aβ42 
aggregate uptake. Scale bars: 20 µm. Showing representative image sections from 
confocal microscopy of multiple co-localization events. Correlation coefficient Pearson’s 






inhibitors of lysosomal enzyme activity and increasing concentrations of EGCG and then 
intracellular Aβ42 aggregate loads were evaluated. Bafilomycin A1 – a potent inhibitor of 
the ATP-dependent proton pump V-ATPase within the lysosomal membrane – prohibits 
acidification of the lysosome and thereby reduces lysosomal enzyme activity (Mauvezin 
and Neufeld, 2015). When SH-EP cells harboring intracellular Aβ42 aggregates were 
additionally treated with Bafilomycin A1, EGCG was no longer able to promote cellular 
aggregate degradation (Figure 14, B). It was further tested, whether lysosomal enzymes 
previously described to be able to degrade amyloid aggregates, were involved in this 
process. Within the lysosome, mainly a family of cysteine proteases – cathepsins – have 
been shown to be able to degrade aggregated Aβ42 peptides (Nixon et al., 2001). 
Especially the family member cathepsin B (CatB) came to attention as it is tightly 
regulated by cystatin C, of which a polymorphism is linked to an increased risk for AD 
(Sun et al., 2008). Furthermore, cathepsin B was described to degrade cellular Aβ42 
aggregates (Mueller-Steiner et al., 2006). Consequently, it was tested whether treating 
Figure 14. EGCG-mediated promotion of cellular Aβ42 degradation is dependent on 
autophagy and lysosomal enzyme activity. (A) ATG5 knockout MEFs show less EGCG-
mediated reduction of cellular Aβ42 aggregate levels when compared to the effect in 
wildtype MEFs. (B) Inhibition of lysosomal acidification and autophagosome-lysosome 
fusion with Bafilomycin A1 does almost completely abrogate EGCG-mediated Aβ42 
aggregate degradation in SH-EP cells. (C) Solely inhibiting the lysosomal enzyme 
cathepsin B using a specific inhibitor (CA074me) does reduce the EGCG-mediated effect 
in the SH-EP cell model. Aβ42 aggregates where quantified from total intensity of 6E10-
antibody signals per cell. Data points show mean of two or three individual experiments 
with error bars representing standard deviation. Student’s t-test was used for statistical 
analysis comparing wildtype or untreated with knockout or inhibitor treated cells, * p < 






SH-EP cells with a selective cathepsin B inhibitor influences the EGCG-mediated 
degradation effect. In fact, only inhibiting this single cathepsin family member was 
sufficient to reduce the EGCG-mediated effect (Figure 14, C). 
Taken together, these results clearly show that the EGCG-mediated increase of cellular 
Aβ42 aggregate degradation is dependent on ATG5-related autophagy and is in particular 
dependent on lysosomal degradation as it can be completely blocked by inhibiting 
lysosomal enzyme activity. 
4.7 EGCG treatment increases maturation of Cathepsin B and boosts 
lysosomal enzyme activity 
As it has been previously reported that EGCG is able to increase acidification of 
lysosomes (Zhong et al., 2015), this effect might be responsible for an increased Aβ42 
aggregate degradation in neuroblastoma SH-EP cells. On the one hand, the optimal 
enzyme activity of CatB is at pH ~6 (Almeida et al., 2000), whereas on the other hand, 
activation of CatB via enzymatic cleavage of its pro-enzyme is increased at low pH 
(Pungerčar et al., 2009). To first investigate whether EGCG has an influence on CatB 
expression and maturation, SH-EP cells were treated with increasing concentrations of 
EGCG and Bafilomycin A1 as a negative control and cell lysates were analyzed by 
Figure 15. EGCG treatment increases CatB maturation. (A) CatB-specific antibody 
detects pro-CatB (46 kDa) and the heavy chain of the mature CatB isoform (25 kDa) in 
SH-EP cells harboring intracellular Aβ42 aggregates. Increasing EGCG concentrations 
positively affect CatB maturation, whereas Bafilomycin A1 completely inhibits maturation 
of the pro-enzyme. (B) Quantification of A. EGCG treatment leads to a decrease of pro-
CatB and increases maturation of CatB, whereas no mature CatB could be detected when 
lysosomal acidification was inhibited with Bafilomycin A1. Bars show signal intensities of 






Western blotting for CatB expression. For detection of the enzyme, a CatB specific 
antibody was used, which is able to recognize the pro-enzyme as well as the maturated, 
active isoform (Figure 15, A). Whereas treatment with Bafilomycin A1 did completely 
prevent the maturation of CatB, reduced levels of the pro-enzyme and increased CatB 
maturation could be observed in EGCG-treated SH-EP cells. Total CatB levels stayed 
relatively stable (Figure 15, B). Next, it was investigated, whether the in-crease in CatB 
maturation does in fact lead to an increased cellular enzymatic activity. For this, a 
fluorescence-quenched CatB substrate (Z-R-R-AMC) was used, which – when cleaved 
by CatB between its arginine residues – becomes released and unquenched. With this 
assay, a potential EGCG-induced increase of enzymatic CatB activity can be quantified 
from the increasing AMC fluorescence intensity over time. SH-EP cells were treated with 
increasing concentrations of EGCG, Bafilomycin A1 and the CatB inhibitor CA074me and 
were subsequently lysed and analyzed for CatB enzyme activity. The fluorescent CatB 
substrate was finally added to SH-EP cell lysates and CatB enzyme activity was 
quantified. EGCG treatment of neuroblastoma cells did result in an increased enzymatic 
activity of CatB in the cell lysate. In contrast, in the control samples, where lysosomal 
activity was inhibited and where EGCG-mediated promotion of Aβ42 degradation is 
Figure 16. EGCG treatment increases CatB enzyme activity in SH-EP cells. (A) 
Cleavage of the CatB-specific fluorescent substrate by SH-EP cell lysates. Treatment of 
living cells with 10 or 20 µM EGCG significantly increase their lysates’ CatB enzyme 
activity. As control, SH-EP cells were treated with Bafilomycin A1 or the CatB inhibitor 
CA074me which resulted in a strong reduction of substrate turnover. Bars show means 
from two individual experiments, error bars represent standard deviation, * p < 0.05, ** 






strongly reduced, the CatB activity was almost completely abolished (Figure 16, A). 
4.8 In-cell potency of EGCG and structural related derivatives strongly 
correlates with modulation of Aβ42 aggregation in vitro 
It has been previously shown that EGCG and related structural derivatives of the catechin 
family inhibit misfolding and aggregation of amyloid-β, α-synuclein, transthyretin and 
other aggregation-prone, disease-associated proteins in vitro (Bieschke et al., 2010; 
Ferreira et al., 2011). Furthermore, it was shown that EGCG remodels mature Aβ42 fibrils 
into SDS-resistant, off-pathway oligomers. Therefore, apart from increasing lysosomal 
enzyme activity in SH-EP cells, a direct effect of EGCG on intracellular Aβ42 aggregates 
might promote their degradation in cells. To test this hypothesis, first EGCG and structural 
related derivatives were analyzed for their effects on preformed Aβ42 aggregate 
degradation in the established cellular compound screening assay. Then, it was further 
assessed, whether derivatives promoting cellular degradation are also modulators of 
Aβ42 aggregation in vitro.  
After treatment of cells with EGCG derivatives (10 µM) for 20 h, total aggregate loads per 
cell were quantified and compared to untreated controls (Figure 17, A). I found that 
unmodified EGCG represented the most potent compound reducing the intracellular Aβ42 
aggregate levels by >50% as observed in the previous experiments (Figure 8, A). 
Interestingly, removal of hydroxyl groups from the gallate ring led to a strong reduction of 
in-cell potency. For dihydroxybenzoate derivatives where only one hydroxyl group was 
removed from the gallate group, still a robust aggregate decreasing effect could be 
measured – nearly as potent as EGCG. Derivatives with only a single hydroxyl group on 
the gallate moiety though, were not sufficient to exhibit an effect in the cell model system. 
As hydroxyl groups on EGCG undergo fast oxidation by forming ketones (Palhano et al., 
2013), additional fluorbenzoate derivatives were synthesized. Presumably these 
compounds are protected from oxidation, but should show similar binding properties as 
hydroxyl groups. Interestingly, a single fluorbenzoate EGC derivative (EGC-3-FB) was 
still – yet less potently – promoting the degradation of cellular Aβ42 aggregates. 
Comparing the potency of the 3,4,5-trihydroxyphenyl chromane with 3,4-dihydroxyphenyl 







Figure 17. EGCG derivatives’ in cell potency correlates with in vitro Aβ42 aggregation 
inhibition. (A) Cellular Aβ42 aggregate levels 20 h after treatment with 10 µM EGCG or 
structural derivatives. EGCG and four derivatives significantly promote degradation of 
intracellular Aβ42 aggregates. (B) Spontaneous aggregation of 10 µM Aβ42 peptides in 
the presence of equimolar amounts of EGCG or derivative monitored by ThT 
fluorescence. (C) Quantification of B shows inhibition of spontaneous Aβ42 aggregation 
or competitive binding to Aβ42 aggregates of EGCG and derivatives with ThT. (D) 
Pearson correlation of derivatives’ in vitro and in cell potency. (E) Structure of EGCG. 
Framed moieties are relevant for potency. (F) Overview of derivatives and their effects. 
Bars show mean of two or three individual experiments, error bars indicate standard 
deviation. Values in percent were normalized to solvent treated control samples. 
Statistical analysis: One-way ANOVA and Pearson’s Correlation Coefficient, * p < 0.05, 






phenyl group for in cell potency and is in line with the stronger effects observed for 
gallocatechol derivatives over catechins on in vitro aggregation effects observed for 
gallocatechol derivatives over catechins on in vitro aggregation (Bieschke et al., 2010). 
Interestingly, the stereochemical orientation is additionally important for compound 
activity. When comparing the activities of EGCG, (-)-GCG and of (+)-GCG, the epi-
orientation clearly shows to exhibit a stronger degradation promoting effect in cells 
(Figure 17, A, C, E).  
To investigate whether the observed compound effects in cells correlate with their in vitro 
effects on Aβ42 aggregation, the compounds were additionally investigated in a Thioflavin 
T (ThT) binding assay. Soluble Aβ42 peptides were incubated in the presence or absence 
of equimolar concentrations of EGCG or EGCG derivatives, and the spontaneous 
formation of Aβ42 aggregates was followed by quantification of ThT fluorescence 
intensity (Figure 17, B). For quantification of the Aβ42 aggregation modulating effect, the 
maximally reached ThT signal intensity compared to untreated control aggregation 
reactions was quantified. It was found that structural modification of EGCG shows a clear 
effect on its inhibition of Aβ42 aggregation in vitro (Figure 17, C). Interestingly, derivatives 
which showed an Aβ42 aggregation inhibiting effect, lead to a reduction of Aβ42 
aggregates in cells. However, it is important to mention that observing a compound effect 
on ThT fluorescence intensity in Aβ42 aggregation studies in vitro can originate from 
different events: from an actual reduction in the formation of β-sheet rich Aβ42 aggregates 
or, from competitive binding of the compound and ThT to β-sheet rich structures. 
Furthermore, a compound-mediated reduction of ThT intensity in Aβ aggregation studies 
does indicate a direct interaction of the compound molecule with Aβ42 aggregates in vitro. 
Interestingly, EGCG derivatives, which were potent promoters of Aβ42 aggregate 
degradation in cells, did also exhibited a strong modulation of Aβ42 aggregation in vitro. 
However, the fluorobenzoate derivatives EGC-3-FB and EGC-4-FB, which presumable 
do not undergo spontaneous oxidation and therefore are more stable molecules, showed 
stronger effects in vitro than in cells. This discrepancy might result from a decreased 
ability to overcome the cellular membrane and spontaneous hydroxyl group oxidation on 
EGCG into ketones might be beneficial for its biological activity, while not being 
detrimental for its potency. To further analyze whether the observed compound effects 
on intracellular Aβ42 aggregates and the effects observed in vitro on Aβ42 aggregation 






I found that the effects of EGCG and its closely related derivatives on Aβ42 aggregation 
in vitro are strongly correlated with the ability of the compounds to promote aggregate 
degradation in cells. The direct effect on Aβ42 aggregation of EGCG and related 
derivatives strongly correlates with their ability to promote aggregate degradation in cells 
(Figure 17, D). This suggests that besides the EGCG-mediated stimulation of lysosomal 
enzyme activity in cells, its ability to directly modulate the formation of Aβ42 aggregates 
may be responsible for promoting cellular Aβ42 aggregate degradation. 
4.9 EGCG directly targets intracellular Aβ42 aggregates 
In order to evaluate, whether EGCG is capable of directly targeting intracellular Aβ42 
aggregates, our collaborators first synthesized a biotin-coupled EGCG derivative for 
aggregate-compound co-localization studies in mammalian cells. Linkage was performed 
at the 3-hydroxyl group of the gallate moiety, fusing it to a single hydroxybenzoate EGCG 
derivative (Figure 18, A). Treatment of intracellular Aβ42 aggregate harboring SH-EP 
cells with this EGCG-Biotin derivative and subsequent staining with a Streptavidin-Cy5 
fluorescent dye, did not result in any specific accumulation of fluorescence at Aβ42-
TAMRA labeled aggregates (Figure 18, B). However, the compound EGC-4-HB, which 
lacks two hydroxyl groups on the gallate moiety was also not able to promote the 
degradation of intracellular Aβ42 aggregates (Figure 17, A). Thus, the absence of any 
co-localization with the EGCG-Biotin derivative, might have simply resulted from the fact, 
that the basic molecular structure used for this experiment was not optimal to interact with 
Aβ42 aggregates. Therefore, using click-chemistry (Kolb et al., 2001) an additional 
fluorescently labeled EGCG derivative was synthesized (EGCG-Rhodamine B), in which 
the rhodamine B fluorophore was coupled at the gallate group that still harbors two 
additional hydroxyl groups (Figure 17, C). To control for unspecific binding of the linker 
or dye itself, additionally a compound consisting of the rhodamine B dye, the ethylene 
glycol linker and the gallate group was generated (Figure 17, E). As TAMRA and 
Rhodamine B highly overlap in their fluorescent spectrum and are therefore unsuitable 
for co-localization studies, HiLyte™ Fluor 488 labeled Aβ42 (Aβ42-HiLyte) aggregates 
were prepared and added to mammalian cells. Strikingly, when SH-EP cells treated with 
the EGCG-Rhodamine B derivative were subsequently analyzed by confocal microscopy, 
a clear co-localization of the compound and intracellular Aβ42-HiLyte aggregates could 
be detected (Figure 17, D). Most notably, when correlating HiLyte and Rhodamine B 






detectable by calculating Pearson’s Correlation Coefficients (Figure 18, D, i., ii.). In 
contrast, the treatment of cells with the control compound (Linker-Rhodamine B) (Figure 
18, E), did not result in any Rhodamine B accumulation at Aβ42 aggregates and only 
showed a very poor correlation of signal intensities (Figure 18, F). This indicates that the 
observed binding of EGCG to intracellular Aβ42 aggregates is highly specific. Thus, the 
ability of EGCG to directly target and dissociate intracellular aggregates might be 







Figure 18. EGCG derivatives for cellular co-localization studies in SH-EP cells. (A) Biotin-
labeled EGCG derivative lacking two hydroxyl groups at the former gallate ring. (B) 
EGCG-Biotin counterstained with Streptavidin-Cy5 shows strong background signal in 
confocal microscopy. Sporadic Cy5 fluorescence clustering does not co-localize with 
intracellular Aβ42-TAMRA aggregates (Pearson’s r = -0.20). (C) Rhodamine B coupled 
EGCG derivative with ethylene glycol linker synthesized using click chemistry. (D) 
Representative image sections show clear co-localization of Aβ42-HiLyte aggregates 
with enrichment of rhodamine fluorescence from EGCG-Rhodamine B derivative 
(Pearson’s r = 0.91 (i.) and 0.73 (ii.)). (E) Rhodamine B control derivative with gallate 
group, ethylene glycol linker and fluorescent dye. (F) No detectable enrichment of 
Rhodamine B control derivative (Pearson’s r = 0.27 and 0.31). Representative images 






4.10 EGCG-mediated remodeling of Aβ42 aggregates facilitates cleavage 
through the lysosomal enzyme Cathepsin B 
Considering that EGCG directly targets intracellular Aβ42 aggregates (Figure 18) and is 
known to induce the formation of off-pathway Aβ42 aggregates (Ehrnhoefer et al., 2008), 
it was obvious to ask whether these Aβ42 aggregate species undergo more efficient 
lysosomal cleavage and degradation. To test this, structural remodeling of Aβ42 peptides 
and aggregates into off-pathway aggregate species was induced by adding EGCG to 
Aβ42 aggregates and the CatB cleavage efficiency of the generated Aβ42 substructures 
was analyzed. To first outline that EGCG directly increases CatB activity in vitro by 
enhancing its enzymatic activity in a cell-free environment, the effect of EGCG on the 
turnover of the chromogenic, CatB specific substrate z-Arg-Arg-amino-4-methylcoumarin 
(Z-R-R-AMC) was analyzed. As a positive control, the CatB inhibitor CA074 was added 
– the unestered equivalent of Ca074me, which was used in the cell-based assay – to 
inhibit CatB enzyme activity. CatB substrate turnover was then followed by monitoring 
AMC fluorescence intensity by cleavage between the arginine residues of Z-R-R-AMC 
(Figure 19, A). For quantification, the turnover rates per minute in the early exponential 
phase were calculated for each reaction. Whereas expectedly, the CatB inhibitor CA074 
significantly reduced CatB enzymatic activity, no direct effect of EGCG on AMC turnover 
Figure 19. Enzymatic cathepsin B activity in vitro is not modulated by EGCG at assay 
concentrations. (A) CatB substrate turnover in presence of EGCG, CatB inhibitor CA074 
and solvent control measured by increasing AMC fluorescence over time. (B) 
Quantification of substrate turnover per minute in exponential phase. CatB inhibitor 
significantly reduces substrate turnover, whereas EGCG shows no effect on CatB enzyme 
activity. Data points and bars depict mean from experiment performed in technical 
triplicates with error bars representing standard deviations. Statistical analysis: One-way 






could be observed (Figure 19, B). Excluding a direct effect of EGCG on CatB activity, it 
was next investigated, whether EGCG-induced Aβ42 aggregates influence the cleavage 
by CatB. Therefore, Aβ42 peptides were first preaggregated for 18 h as previously 
described (3.2). Then, EGCG or DMSO was added to preformed Aβ42 aggregates and 
samples were incubated for an additional 24 h. To assess whether EGCG was able to 
induce the aggregate remodeling, the morphologies of preformed untreated and treated 
Aβ42 aggregates were analyzed by AFM and EM. Here, in line with previous studies, it 
could be observed that fibrillar Aβ42 aggregates are partly disrupted and that the 
formation of oligomeric structures is induced (Figure 20, A, B). The formation of EGCG-
Figure 20. EGCG-induced Aβ42 aggregate remodeling. (A) Incubation of 10 µM high 
molecular weight, fibrillar Aβ42 aggregates with excess amounts of EGCG for 24 h results 
in fibril disruption and formation of amorphous substructures. Samples analyzed by AFM. 
(B) Similar morphological changes are observed when samples are analyzed by TEM. 
(C) Aggregation of 10 µM soluble Aβ42 peptides in presence of equimolar concentrations 
of EGCG hinders fibril formation and results in the formation of stable amorphous Aβ42 
oligomers. Samples analyzed by AFM. Scale bars: 500 nm. Representative image 






induced Aβ42 aggregate species was even more pronounced, when Aβ42 peptide 
aggregation reactions were performed in the presence of EGCG, resulting in an almost 
complete off-pathway oligomer population (Figure 20, C).  
To quantify the EGCG-mediated remodeling of preformed Aβ42 aggregates, the reaction 
products were additionally analyzed by density gradient centrifugation. Therefore, the 
recently published QIAD method was slightly modified. With this method, compound 
effects on the formation of aggregate species and their size distribution can be precisely 
monitored (Brener et al., 2015). In the density gradient, the preformed Aβ42 aggregates 
Figure 21. Quantification of EGCG-mediated structural Aβ42 aggregate remodeling 
using gradient centrifugation. (A) Preformed Aβ42 aggregate solutions (DMSO) consist 
of various protein aggregate sizes resembled by a wide distribution over gradient 
fractions. Enrichment of high molecular weight Aβ42 aggregates in the pellet fraction is 
detected. Addition of EGCG (+ EGCG) redirects Aβ42 aggregates into a defined 
subspecies, which strongly accumulates in fraction #12. Data bars show mean from 
technical triplicates of one representative experiment. Error bars represent standard 






were distributed relatively equally over fractions 10 to 14 and also enriched in the pellet 
fraction (15) (DMSO, Figure 21, A), indicating the presence of mainly large Aβ42 
aggregate species and some smaller structures. When EGCG-remodeling was 
conducted, the aggregate distribution changed indicating the formation of smaller 
aggregate species. Interestingly, a strong enrichment of Aβ42 species within fraction #12 
could be observed (+EGCG, Figure 21, A), which most likely represents the previously 
characterized, EGCG-induced oligomeric species (Bieschke et al., 2011).  
To next assess whether EGCG-mediated remodeling of preformed Aβ42 aggregates 
influences their cleavage through the lysosomal protease CatB, Aβ42 aggregate species 
were produced and digested with the lysosomal enzyme. To evaluate whether EGCG-
mediated remodeling does indeed facilitate enzyme cleavage, reaction products were 
analyzed in dot blot assays for Aβ content. Additionally, the specific degradation of SDS-
stable Aβ42 aggregate species by CatB was evaluated by filter retardation assays. It 
Figure 22. EGCG-mediated Aβ42 aggregate remodeling facilitates lysosomal enzyme 
cleavage. (A) In vitro CatB digestion of fibrillar and EGCG-induced Aβ42 aggregate 
species. 10 µM preformed Aβ42 aggregates were digested with 5 µg/ml CatB for 4 h and 
analyzed by dot blot assays. EGCG-induced Aβ42 subspecies are most efficiently 
degraded. (B) Specific analysis of SDS-stable Aβ42 aggregates in filter retardation 
assays. CatB cleavage of solvent treated, SDS-stable Aβ42 aggregates results in Aβ 
signal increase of SDS-FRA. EGCG-induced, SDS-stable Aβ42 aggregate subspecies 
are not detectable in SDS-FRAs after CatB digestion. Data bars depict means from one 






could be seen that, fibrillar Aβ42 aggregates (as shown in Figure 21) are partially 
degraded by cathepsin B in vitro, reducing the abundance of Aβ42 aggregate species by 
56% (DMSO, Figure 22, A). However, when mature fibrillar aggregates are incubated 
with EGCG for 24 h to induce their remodeling prior to enzymatic digestion, cathepsin B 
cleavage is increased, leading to a reduction of 62% (+EGCG disaggr., Figure 22, A). 
This effect is even more pronounced, when Aβ42 aggregates were preformed in the 
presence of EGCG. Under this condition, almost the whole aggregate population consists 
of the previously described, SDS-stable, off-pathway oligomeric aggregate species 
(Figure 20, C), which are indeed highly detergent stable, but surprisingly were efficiently 
degraded by the lysosomal enzyme cathepsin B (+EGCG aggr., Figure 22, A). Strikingly, 
when only analyzing the degradation of SDS-stable Aβ42 aggregate species, a complete 
enzymatic digestion of the EGCG-induced aggregate species could be observed, 
whereas cathepsin B was not able to degrade SDS-stable, fibrillar Aβ42 aggregates 
(Figure 22, B). This strongly indicates that the direct effect of EGCG on fibrillar Aβ42 
aggregates leads to the formation of structures, which are much more easily degraded 
by lysosomal enzymes – a key pathway in cellular Aβ42 proteolysis and the potential 








Previous approaches pursued to reduce cellular Aβ42 aggregate loads mainly focused 
on enzymatic inhibition of APP cleaving enzymes or antibody-mediated immunological 
clearance of Aβ42 plaques. Targeting intracellular Aβ42 aggregates with small molecules 
potentially represents a promising approach to slow AD progression by increasing 
insufficient cellular clearance. Additionally, compound-mediated modification and 
reduction of intracellular Aβ42 aggregates might reduce their cell-to-cell transfer and 
pathological spreading of misfolded Aβ42 species in AD (Bieschke, 2013; Eisele et al., 
2015). Aβ42 lowering drugs developed to date, mainly targeted the production of 
aggregation-prone Aβ42 peptides or the reduction of extracellular Aβ plaques (Cummings 
et al., 2017). Additionally, previous small molecule screening assays mainly tried to 
identify in vitro Aβ42 aggregation inhibitors (Wang et al., 2014) or – in a cellular context 
– stimulators of cellular protein degradation pathways such as proteasome and 
autophagy activators (Eisele et al., 2015; Hwang et al., 2017). In this study, using a cell-
based high-throughput compound screening assay it was aimed to identify small 
molecules, which significantly reduce the abundance of intracellular Aβ42 aggregates. 
Further, the mechanism behind the cellular Aβ42 aggregate reductive effect of the most 
potent hit compound – EGCG – was investigated. 
5.1 A cell-based, high-throughput compound screening assay recapitulating 
intracellular Aβ42 aggregate pathology 
A cell-based compound screening assay, which is able to identify small molecules 
lowering intracellular Aβ42 aggregate load needs to clearly recapitulate features of in vivo 
aggregate pathology. Preformed Aβ42 aggregate species have been shown to convert 
soluble Aβ peptides into an aggregated state in a prion-like seeding process and 
continuous cell-to-cell spreading of Aβ42 species might drive AD progression. Thus, a 
suitable cellular model of intracellular Aβ42 formation for compound screening should 
make use of similar uptake mechanisms as observed in vivo. A major pathway for 
internalization of large gulps – including misfolded, aggregated proteins – from the 
extracellular space (Wang et al., 2017) is macropinocytosis. This pathway was described 
to be a mechanism through which uptake and subsequent degradation of protein 
aggregates within the endolysosomal system takes place (Mandrekar et al., 2009). 
Furthermore, when uptake through macropinocytosis is followed by insufficient clearance, 






Zeineddine and Yerbury, 2015). After internalization, intracellular Aβ42 aggregates in vivo 
mainly accumulate in enlarged multivesicular bodies – a specialized subset of 
endosomes, which are able to fuse with lysosomes for subsequent degradation (R. A. 
Nixon, 2013). 
In the work of this thesis, first a suitable cellular model system for uptake and 
accumulation of intracellular Aβ42 aggregates was established. Modelling intracellular 
Aβ42 aggregate pathology and their deposition in neuroblastoma SH-EP cells using 
preformed, fluorescently labeled Aβ42 aggregates showed to involve actin-dependent, 
lipid-raft mediated macropinocytosis for aggregate uptake. Furthermore, the formation of 
SDS-stable, ThT-positive Aβ42 intracellular aggregates accumulating in the 
endolysosomal system could be observed. Thus, this cell model clearly exhibits main 
characteristics of intracellular in vivo pathology (Biancalana and Koide, 2010; Krafft et al., 
2003; Takahashi et al., 2017). Using fluorescently labeled Aβ42 aggregates, the 
intracellular aggregate formation can additionally be easily monitored and quantified. This 
model could be effectively scaled up to a semi-automated, high-throughput capable, cell-
based compound screening assay. Previously established assays for the identification of 
AD-modifying drugs mainly involved cell-free, in vitro aggregation inhibition assays (Wang 
et al., 2014). Compounds identified with these methods need extensive downstream 
investigations to analyze their in-cell potency. Therefore, cell-based compound screening 
assays are a powerful tool to directly identify biologically active small molecules (Michelini 
et al., 2010). 
5.2 Direct Aβ42 aggregate targeting compounds reduce cellular aggregate 
load, seeding activity and Aβ42-induced toxicity 
To elucidate the practicability of the assay, a focused proof-of-principle screen with a 
preselected polyphenolic compound library was performed. This chemical subgroup was 
found to effectively inhibit Aβ42 aggregate formation in cell-free assays (Bieschke, 2013; 
Stefani and Rigacci, 2013) and was therefore investigated for its potency to reduce the 
abundance of cellular Aβ42 aggregates. The cell-based compound screening assay 
efficiently identified 5 compounds within the tested polyphenol library, which significantly 
reduce cellular Aβ42 aggregates. As it was found that the most potent compound – EGCG 
– did partially quench the fluorescence of TAMRA-labeled Aβ42 aggregates, intensive 
validation experiments were performed. Antibody-based immunofluorescent and 






intracellular Aβ42 aggregate levels. High-throughput screening assays often make use of 
an increase or a decrease in bioluminescence or fluorescence to identify hit molecules 
(An, 2009; Fan and Wood, 2007). Subsequent validation experiments are of crucial 
importance as functional moieties of the compound molecule are able to interfere with 
assay readout signals. In the case of fluorescence, this can be caused by changes in pH, 
absorbance of the compound within the excitation or emission spectrum or by excited 
state reactions, energy transfer, complex-formation and collisional quenching (Simeonov 
and Davis, 2004). Interestingly, when the direct quenching effect of EGCG on the TAMRA 
fluorophore was evaluated in a cell-free environment, no quenching effect could be 
detected. However, EGCG quenched TAMRA fluorescence when coupled to Aβ42. As 
EGCG is known to bind to Aβ42 peptides and aggregates (Bieschke et al., 2010), this 
might be due to EGCG accumulation in close proximity to the fluorophore. Whereas, when 
the fluorophore and EGCG co-exist in solution, no direct interaction takes place and no 
quenching can be observed. Additionally, EGCG-induced remodeling of Aβ42-TAMRA 
aggregates might affect fluorescence due to changes in the amino acid surrounding of 
the fluorophore. Thus, especially when the impact of small molecules on fluorescently 
labeled protein aggregates is investigated, intensive validation of compound-mediated 
effects in independent assays is essential. 
Besides reducing intracellular Aβ42 aggregate load, EGCG treatment of SH-EP cells with 
intracellular Aβ42 aggregates additionally resulted in the reduction of the cell extracts’ 
seeding activity. While it remains unclear whether this effect is in fact mediated through 
a structural remodeling of Aβ42 aggregates into off-pathway structures or through the 
sole reduction of cellular Aβ42 aggregates, it shows that direct aggregate targeting 
compounds provide an effective strategy to reduce seeding-activity in a cellular context. 
Additionally, EGCG treatment showed to reduce Aβ42-induced mitochondrial toxicity in 
SH-EP cells as well as in primary neurons of rat hippocampi. Observing that a rescue of 
Aβ42 aggregate-induced can be achieved with EGCG treatment indicates that it’s cellular 
modulation of Aβ42 aggregate levels is beneficial for cell viability. 
5.3 A potential mechanism of the EGCG-induced reduction of intracellular 
Aβ42 aggregates 
Several cellular Aβ42 aggregate lowering small molecules were previously identified 
(Wolfe, 2008). In fact, treatment with the most potent compound – EGCG – was 






et al., 2015; Li et al., 2006; Lin et al., 2009). However, although numerous potential 
cellular targets of EGCG were identified (Chang et al., 2015; Li et al., 2006; Lin et al., 
2009), the main underlying mechanism responsible for its aggregate degrading effect in 
cells is still unknown. Therefore, this work further systematically investigated the 
underlying mechanism of EGCG-mediated reduction of the cellular Aβ42 aggregate load. 
Due to the fact that intracellular Aβ42 aggregates in SH-EP cells mainly accumulated in 
lysosomes and cathepsins were previously described to be involved in Aβ aggregate 
clearance (Mueller-Steiner et al., 2006), I hypothesized that its aggregate degradation 
promoting effect is exhibited through lysosomal degradation. Systematic inhibition of 
autophagy, lysosomal acidification and the lysosomal enzyme CatB revealed that the 
EGCG-mediated reduction of the intracellular Aβ42 aggregate load is dependent on 
lysosomal function and further on enzymatic activity of CatB. Total inhibition of CatB 
maturation completely abrogated the EGCG-mediated effect. As EGCG was previously 
described to enhance lysosomal acidification and might thereby enhance Aβ42 aggregate 
cleavage (Zhou et al., 2014), it was tested whether EGCG treatment increases lysosomal 
enzyme activity in SH-EP cells. Interestingly, even in the absence of intracellular Aβ42 
aggregates, EGCG increased lysosomal enzyme activity. Additionally, an increased 
maturation of CatB through EGCG treatment could be detected. This increase might 
represent a potential mechanism for the increased degradation of intracellular Aβ42 
degradation after EGCG treatment. Interestingly, EGCG was recently described to 
increase lysosomal acidification and thereby counteract Epstein-Barr virus infection 
(Zhong et al., 2015). However, if enhancement of lysosomal enzyme activity through 
increased acidification is the main mechanism for EGCG’s strong degradative effect, one 
would expect to see a reductive effect of EGCG when lysosomal acidification is inhibited 
with Bafilomycin A1. Complete lysosomal enzyme inhibition though did fully block the 
EGCG-mediated increase of Aβ42 aggregate degradation and even high EGCG 
concentrations (30 µM) were not able to initiate a reduction of cellular Aβ42 aggregate 
levels. Therefore, besides EGCG-induced increase of lysosomal acidification, I 
hypothesized that an additional independent mechanism might be predominantly 
responsible for its Aβ42 aggregate lowering effect. 
The addition of EGCG to spontaneous Aβ42 peptide aggregation reactions was shown 
to inhibit the formation of fibrillar Aβ42 aggregates and leads to the formation of an off-






preformed Aβ42 aggregates induces the remodeling of fibrillar species (Bieschke et al., 
2010). As the EGCG-mediated reduction of intracellular Aβ42 aggregates was found here 
to be mediated through lysosomal degradation and as it was previously described that 
the remodeling of protein aggregates in lattice corneal dystrophy facilitates their 
proteolytic degradation (Stenvang et al., 2016), I hypothesized that the structural 
remodeling of Aβ42 aggregates might increase degradation through lysosomal enzymes 
and thereby lead to an increased reduction of intracellular Aβ42 load. Comparing the 
reduction of intracellular Aβ42 aggregates of EGCG and structural derivatives revealed 
that compounds, which show in vitro Aβ42 aggregation modulation, are potent in reducing 
cellular Aβ42 load. This suggested that a direct in cell interaction of the compound 
molecules with Aβ42 aggregates might be responsible for the observed effects. A 
prerequisite for this proposed mode of action is that EGCG is indeed able to bind to Aβ42 
aggregates in cells. Even though in vitro binding of fibrillar Aβ42 aggregates has been 
shown (Bieschke et al., 2010), in cell binding evidence was lacking to date. In this work, 
labeling of EGCG with a rhodamine fluorophore did clearly show that EGCG directly binds 
intracellularly accumulating Aβ42 aggregates. As EGCG is able to bind to Aβ42 
aggregates in cells, I hypothesized that the structural remodeling of Aβ42 aggregates 
facilitates their cleavage through lysosomal proteases. This could represent the 
mechanistic explanation for the increased degradation of intracellular Aβ42 aggregates 
upon compound treatment. EGCG-treatment of preformed Aβ42 aggregates partially 
disrupted and disassembled fibrillar structures into smaller peptide species in vitro. 
Interestingly, the induced structures are more SDS-stable when compared to fibrillar 
Aβ42 aggregates. However, the evaluation of Aβ42 aggregate degradation with the 
lysosomal protease CatB of native and EGCG-remodeled Aβ42 aggregates revealed that 
these structures– even though highly detergent stable – are more efficiently degraded by 
the lysosomal enzyme. Furthermore, when Aβ42 aggregates were preformed in the 






population, also a complete degradation of Aβ42 aggregates through CatB could be 
detected. In contrast, CatB was not able to degrade SDS-stable fibrillar Aβ42 aggregates.  
Based on these results, we propose a mechanism for EGCG-induced reduction of cellular 
Aβ42 aggregate load. EGCG is able to cross the cellular membrane and bind to 
intracellularly accumulating amyloid aggregates. Binding to intracellular fibrillar Aβ42 
aggregates induces structural remodeling into off-pathway structures. In contrast to 
fibrillar Aβ42 aggregates, these EGCG-induced oligomer species can be effectively 
degraded through lysosomal enzymes and thereby intracellular Aβ42 aggregate load is 
reduced. 
Figure 23. Model of EGCG-mediated reduction of cellular Aβ42 aggregates. Preformed 
Aβ42 aggregates are internalized via lipid-raft mediated macropinocytosis into early and 
late endosomes, which subsequently fuse with lysosomes for aggregate degradation. 
Fibrillar Aβ42 aggregates are inefficiently cleaved by lysosomal cathepsins and 
accumulate. Preventing lysosomal acidification and thereby CatB maturation or inhibition 
of CatB with a specific inhibitor blocks lysosomal degradation of Aβ42 aggregates. EGCG 
is able to enter cells and bind to intracellular Aβ42 aggregates potentially inducing their 
structural remodeling in cells. EGCG-induced off-pathway structures are efficiently 






Various approaches have been undertaken to lower Aβ42 load in the brain of AD patients 
(Cummings et al., 2017). With this work, a novel approach and mechanism is presented. 
Identifying compounds, which selectively reduce intracellular Aβ42 aggregates through 
enhancing endogenous clearance mechanisms by changing compact, fibrillar amyloid 
aggregates into amorphous subspecies might be an effective Aβ42 lowering approach. 
Especially with the fact in mind that AD is a disease of the elderly and that with increasing 
age cellular protein clearance becomes inefficient (Tan et al., 2014), these small 
molecules might thereby counteract the deficient amyloid degradation. Additionally, as 
mutations in clearance mechanisms are causative for AD and insufficient clearance of 
protein aggregates is thought to be a driver in proteinopathies (Bloomfield and Kay, 2016; 
Zeineddine and Yerbury, 2015), this approach might be very specific in targeting common 
malfunctions in neurodegeneration responsible for progression in these diseases. It is to 
state that especially cathepsin-mediated lysosomal degradation is controversially 
discussed in AD pathogenesis. Cathepsin-mediated amyloid cleavage has been 
suspected to increase the production of aggregation-prone Aβ42 species (Haque et al., 
2008). Therefore, cathepsin inhibitors were proposed and evaluated as potential disease-
modifying drugs. However, these did not exhibit strong beneficial effects in preclinical 
studies and more recent evidence, in line with this study, supports the idea that cathepsin 
are major essential enzymes for maintaining cellular protein homeostasis, are important 
for degradation of accumulating protein aggregates and mutations in cathepsins even 
cause neurodegeneration (R. A. Nixon, 2013; Perlenfein and Murphy, 2017; Sun et al., 
2008) Thus, enhancing cathepsin-mediated, lysosomal clearance – e.g. through direct 
Aβ aggregate binding compounds represent a promising approach to increase insufficient 
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